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ABSTRACT 
Gregery Woss: Development of Peptide Based E3 Ligase Reporter 
(Under the direction of Nancy L. Allbritton) 
This dissertation describes the development of a new analytical tool capable of analyzing 
E3 ligase activity, a critical element in the ubiquitin proteasome system.  This was accomplished 
through the development of a novel class of peptide-based fluorescent E3 ligase reporters which 
are intended to be analyzed by capillary electrophoresis (CE). These E3 ligase reporters 
incorporate a degradation signal, or degron, which is recognized and ubiquitinated by an E3 
ligase, as well as a fluorescent tag to facilitate detection by laser induced fluorescence (LIF).  In 
order to identify potent degrons, a library of E3 ligase reporters incorporating degrons from 
various sources was synthesized.  These reporters were characterized in cell lysates, then 
optimized to produce substrates that would be efficiently ubiquitinated in cells.  In addition to 
working with minimal degron sequences, an expanded sub-library of reporters based around the 
degron isolated from p53 was characterized in order to identify a compact degron element and 
investigate its ubiquitination kinetics and specificity.  In order to circumvent peptidase-mediated 
degradation, a traditional weakness of peptide reporters, investigations were also carried out to 
develop novel degradation-resistant E3 ligase reporters incorporating β-hairpin secondary 
structures.  Serendipitously, a β-hairpin that was both peptidase-resistant and functioned as an E3 
ligase reporter was identified. Finally, electrophoretic separation conditions for the analysis of 
E3 ligase peptide reporters were identified, and ubiquitination of E3 ligase reporters in cell 
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lysates was observed by CE-LIF.  This dissertation lays the groundwork for future development 
of next generation peptide-based E3 ligase reporters. 
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Chapter 1: Introduction 
1.1 The Ubiquitin Proteasome System 
The ubiquitin proteasome system (UPS) is an essential enzymatic pathway that is crucial to 
cell homeostasis, migration, and proliferation of eukaryotic cells.1  The UPS is comprised of 
several families of enzymes and collectively functions to degrade damaged, misfolded, or excess 
proteins, to modulate the abundance of key regulatory proteins, and to post-translationally 
modify proteins via the conjugation of the small protein ubiquitin (ubiquitination).2-4  
Ubiquitination is at the heart of the UPS’s tight regulation, and is carried out by a cavalcade of 
progressively specific enzyme families (Figure 1.1).   
The process begins when ubiquitin, a 76-amino acid protein found throughout the cell, is 
activated by an E1 activating enzyme (E1) in an ATP-driven process.  This results in the 
formation of a high-energy thioester bond between ubiquitin and the E1.  This complex then 
interacts with a second family of enzymes, an E2 ubiquitin-conjugating enzyme (E2), and the 
activated ubiquitin is transferred to form a new ubiquitin-E2 complex.  A third class of enzymes, 
the E3 ubiquitin ligases (E3), mediate the transfer of ubiquitin directly (RING family of E3 
ligases) or indirectly (HECT family of E3 ligases) to a targeted protein.2  Ubiquitin forms an 
isopeptide bond via the amine group on a proximal lysine (K) or ornithine (O) residue on the 
targeted protein.   Following the initial ubiquitination event, additional ubiquitin proteins can be 
conjugated to one of the original ubiquitin moieties via one of seven lysine residues (e.g. K11, 
K48, or K63) to form a poly-ubiquitin chain.5  The structure and length of the poly-ubiquitin 
chain dictate the effect ubiquitination has on a protein; for example, poly-ubiquitin chains 
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formed on the K48 residue is recognized by regulatory elements of the proteasome, while poly-
ubiquitin chains formed on the K63 residue play a role in cell signaling, endocytic trafficking, 
and DNA damage repair.5  While the UPS is comprised of a conglomeration of enzymes, E3 
ligases are largely responsible for the UPS’s high level of specificity. E3 ligases recognize 
targeted proteins through a degradation signal, or a degron.  Degrons can be simple amino acid 
sequences or more complex, requiring post-translational modifications such as phosphorylation 
or oxidation.3  The role that E3 ligases play as the ultimate arbitrators of ubiquitination is 
reflected in their expansive diversity, with over 600 distinct E3 ligases documented in humans.6    
Degradation of proteins via the UPS is catalyzed by the proteasome.  The 26S proteasome is 
a large, multi-unit protein consisting of a 19S regulatory cap and a 20S core particle.4  The 19S 
cap has multiple functions: it recognizes proteins targeted for degradation through poly-ubiquitin 
chains, cleaves ubiquitin from proteins prior to degradation, and unfolds and threads the protein 
into the 20S core for degradation.  The 20S core of the proteasome is barrel shaped and contains 
catalytic sites with trypsin-like, chymotrypsin-like, and peptidylglutamyl-peptide hydrolyzing 
proteolytic activities.  These catalytic sites are responsible for the cleavage of proteins into short 
peptide fragments.  Adding a further level of refinement to the UPS are deubiquitinating 
enzymes (DUBs), which selectively cleave ubiquitin from substrates.  DUBs work in opposition 
to E3 ligases, rescuing targeted proteins from being degraded by the proteasome and allowing 
ubiquitin to be efficiently recycled by the cell. 
While not the focus of the research presented here, it is worth noting that the UPS is 
paralleled by several ubiquitin-like systems (UbL).  UbLs make use of proteins analogous to 
ubiquitin, E1, E2, E3, and DUB proteins.  UbLs have been shown to play a role in many 
important cellular processes, including DNA repair and transcriptional regulation.7  Prominent 
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examples of UbLs include the small ubiquitin-like modifier (SUMO), neural precursor cell 
expressed developmentally downregulated protein 8 (NEDD8), and interferon stimulated gene 
15 (ISG15). 
1.2 Importance of the Ubiquitin Proteasome System in Biomedical Research 
Dysregulation of UPS components, such as E3 ligases and the proteasome, have been 
observed in several disorders, including multiple cancers and neurodegenerative diseases.8  
These observations, paired with the central role the UPS plays in cell homeostasis though 
ubiquitination and though the degradation of proteins, have made components of the UPS the 
foci of intense research and interest.9  This interest rapidly increased following the clinical 
success of bortezomib (Velcade®), a small molecule inhibitor of the proteasome, which 
demonstrated the potential benefits of developing novel therapeutics targeting the UPS.10, 11   
Bortezomib was approved in 2007 for the treatment of multiple myeloma, and later for acute 
myeloid leukemia (AML).10  AML is a cancer of the myeloid line of blood cells found in bone 
marrow. These cancerous cells quickly crowd out normal cells, which interferes with production 
of healthy blood cells, in turn resulting in the development of anemia, infection, and eventual 
death. AML predominantly afflicts older patients, accounting for 14,590 new cases (30%) of 
newly diagnosed leukemia among elderly patients in 2013, according to the American Cancer 
Society. The majority of patients with AML are precluded from undergoing conventional 
intensive chemotherapy due to the high risk of treatment-related mortality.12  This results in a 
grim prognosis for this group of patients, with a five-year survival rate of 25%.  The 
development of Bortezomib and its successor Carfilzomib (Kyprolis®) proved a major 
breakthrough in the treatment of AML; a number of studies have since demonstrated the efficacy 
of Bortezomib in treatment of AML, both as a standalone therapeutic and in combination with 
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other drugs.13, 14  Dysregulation of protein production in AML creates an overreliance on the 
proteasome to degrade these proteins.  As a result, incomplete inhibition of the proteasome 
proves too stressful for cancer cells to overcome, while simultaneously being less cytotoxic to 
healthy cells than traditional chemotherapeutics.   
In addition to multiple myeloma and AML, members of the UPS are suspected to play a 
direct role in other cancers and neurodegenerative diseases.10, 15, 16 Though there are conflicting 
reports, decreased proteasome activity is suspected to play a key role in conformational diseases 
such as Parkinson’s and Huntington’s disease.17  These diseases are characterized by the 
accumulation of misfolded proteins, such as amyloid plaques, with decreased proteasome 
activity suggesting it may be an attractive target for inhibition. Additionally, dysregulation of 
other UPS components has been observed in neurodegenerative diseases, such as the frame-
shifted ubiquitin UBB+1.18  This mutated form of ubiquitin contains an extra 19 amino acids on 
the Ub C-terminus preventing it from being activated by E1 enzymes, potentially putting 
additional stress on the UPS.  Furthermore, the tumor suppressor p53 and its E3 ligase Hdm2 are 
well known to play a role in cancers, highlighting an additional role for the UPS in disease.19  
In healthy cells, regulation of p53 is maintained by constant degradation; however, when 
cells are subjected to genotoxic stress, p53 degradation is suppressed.20 This allows p53 to 
accumulate in cells, which in turn leads to an upregulation of genes associated with apoptosis or 
growth. Because of p53’s dysregulation in many cancers, Hdm2 has become the target of intense 
interest. Finally, the dysregulation of DUBs such as CYLD and USP9 have been observed in 
cancers, suggesting they likely play an important role as oncoproteins.14, 21 
These observations precipitated a push to develop new therapeutics targeting specific 
dysregulated enzymes upstream of the proteasome, such as E3 ligases and deubiquitinating 
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enzymes (DUBs) and many such inhibitors are currently in clinical trials.9  Despite the drive to 
develop these novel drugs targeting the UPS, current analytical tools used to investigate the 
enzymatic activity of these components leave much to be desired, most conspicuously there is no 
assay currently capable of directly measuring the activity of UPS components, such as E3 
ligases, in clinical samples. 
1.3 Survey of Current Techniques for Measuring E3 Ligase Activity in the UPS 
Several technologies including Western blots, qPCR (quantitative polymerase chain 
reaction), and FRET (Förster resonance energy transfer) sensors, are represented widely in the 
literature for measuring E3 ligase activity.  Each technique has advantages and drawbacks, 
requiring them to be employed thoughtfully and under controlled conditions. 
Western blots are among the most popular techniques for investigating specific enzymes, and 
are considered the gold standard of ubiquitination experiments.  This workhorse technique is 
highly selective, does not require genetic engineering, and does not require specialized 
instrumentation.  In a typical Western blot analysis, cells are lysed and their contents separated 
based on molecular size using sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-
PAGE).  The proteins are then transferred to a nitrocellulose membrane where they are incubated 
with antibodies specific for the protein of interest.  Unbound antibodies are washed away and the 
sample is incubated with a second antibody conjugated to a fluorescent handle.  The sample is 
imaged and the amount of targeted protein is quantified.  While very common, Western blots 
suffer from several limitations.  Western blots measure total amount of an enzyme, such as an E3 
ligase; however, this may not necessarily be a good proxy for that enzyme’s activity, because it 
does not account for modifications such as phosphorylation or small mutations that may affect 
functionality.  Additionally, traditional Western blots require relatively large sample sizes, which 
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limits their usefulness in analyzing samples from patients, where total cell numbers are low.  
This bulk analysis only returns information on the average amount of enzyme in a sample, 
potentially masking important subpopulations within the sample. Finally, while many antibodies 
are commercially available, Western blot analysis is restricted by the lack of appropriate 
antibodies.   
Reverse transcription polymerase chain reaction (RT-PCR) is a powerful analytical technique 
that overcomes the size limitations of Western blots, allowing for measurement of mRNA in 
samples as small as single cells.  The technique utilizes reverse transcriptase to convert mRNA 
into DNA and makes use of real time PCR (qPCR) to quantify the amount of the newly produced 
complementary DNA (cDNA).  The technique is compatible with very small sample sizes (≥ 1 
cell) and does not require genetic engineering approaches, so it is capable of analyzing patient 
samples.  However, this technique does not directly measure protein activity or protein 
abundance, instead measuring mRNA levels for a protein, an indicator twice removed from the 
desired metric.   
Förster resonance energy transfer (FRET) sensors allow for sensitive and high throughput 
screens of E3 ligase activity in cells.22  E3 ligase FRET sensors work by genetically engineering 
cells to produce an E3 ligase substrate with a fluorescent donor molecule and a ubiquitin with an 
acceptor molecule.  The activity of the E3 ligase then brings the acceptor and donor molecule 
into close proximity, allowing for the detection of a fluorescent signal when interrogated with the 
appropriate wavelength of light.  This system is particularly ideal for screening large numbers of 
compounds for inhibitory activity.  FRET sensors have the benefit of directly measuring E3 
ligase activity, and are highly sensitive, allowing for use with small numbers of engineered cells.  
The major drawback of the technique is that it requires genetic engineering approaches, making 
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for long system development times and making the technique impractical for investigation of 
primary cells. 
1.4 E3 Ligase Peptide Reporters for Chemical Cytometry 
While each of the previously described techniques is powerful in the proper context, none 
meet the high requirements required to analyze patient samples (Figure 1.2).  Chemical 
cytometry overcomes these limitations by directly measuring enzyme activity in small samples 
without the need for genetic engineering.  This strategy revolves around using externally 
synthesized probes, such as peptide reporters labeled with fluorescein, and introducing them into 
a cellular environment, where they act as a substrate for an enzyme of interest. The reporters are 
directly modified by the enzyme of interest and substrate and product can readily be quantified 
by chemical cytometry techniques.  Post-translational modifications, (e.g., phosphorylation) can 
be quantified in samples as small as single cells by separating analytes via capillary 
electrophoresis (CE) and detecting them with highly sensitive laser induced fluorescence 
(LIF).23-26 
Peptide-based reporters can be synthesized using the well-established technique of solid 
phase peptide synthesis (SPPS), allowing for rapid prototyping and bypassing genetic 
engineering requirements.  Reporters are directly modified by enzymes, yielding a direct 
measurement of enzyme activity.  And finally, the extremely small sample size requirements, 
exceptional separation efficiency, and peak capacity of CE-LIF allow for the detection of 
enzymatic activity in samples as small as single cells (~1 pL) with limits of detection as low as 
10-21 mol.23 
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1.5 β-Hairpins Protectides 
One drawback to traditional peptide reporters is they are often rapidly degraded by 
intracellular peptidases.  It has been reported that this degradation can be diminished through the 
incorporation of unnatural amino acids, but this process must be carefully tailored to individual 
peptide reporters, requiring careful characterization following each modification.25 Secondary 
structures, such as β-hairpins have been shown to increase peptide lifetimes in the presence of 
intracellular peptidases.27  In collaboration with and building upon work done by members of the 
Waters laboratory, initial plans were to append such a structure, termed a protectide, to a peptide 
reporter as a means of increasing the reporter’s lifetime in the face of peptidases.28  
Serendipitously, however, previous group members in the Waters and Allbritton group 
discovered the β-hairpin peptide that the Waters group designed served as an independent 
degron.  Chapter four of this work describes the characterization of this highly robust peptide 
reporter. 
1.6 Capillary Electrophoresis 
Capillary electrophoresis is a separations technique first described by Jorgenson and 
Lukacs.29   CE separation occurs in a fused silica capillary with a small inner diameter that is 
filled with a current-carrying buffer solution.  Following introduction of sample, both ends of the 
capillary are immersed in buffer and a high electric voltage is applied across the capillary.  
Analytes migrate within the capillary based on their electrophoretic mobility (a combination of 
their charge, size, and shape) and electroosmotic flow of the buffer.  The electrophoretic mobility 
of a sphere can be approximated using equations 1.1 and 1.2, while the velocity of a species in 
CE is defined by equation 1.3.29 
Equation 1.1: 
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𝜇 =
𝑞
6𝜋𝜂𝑟
 
𝜇 = electrophoretic mobility 
𝑞 = particle charge 
𝜂 = buffer viscosity  
𝑟 = Stoke’s radius (Equation 1.2) 
Equation 1.2 
𝑀 =
4𝜋𝑟3𝑉
3
 
𝑀 = mass 
𝑟 = Stoke’s radius 
𝑉 = partial specific volume  
Equation 1.3 
𝑣 = (𝜇𝑒𝑝 + 𝜇𝑒𝑜)𝐸 
𝑣 = velocity 
𝜇𝑒𝑝 = electrophoretic mobility 
𝜇𝑒𝑜 = electroosmotic mobility  
𝐸 = applied electric field 
 
The electroosmotic flow of buffer is a phenomenon that results from the small internal 
diameter of the capillary and the charged inner surface of that capillary. For a fused silica 
capillary, this charge is dependent on the buffer utilized as well as any surface modifications.  
Capillaries without chemical surface modifications, a neutral or basic buffer will result in a more 
highly negatively charged capillary surface, attracting a large number of positively charged ions 
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to associate with the inner walls.  This causes negative ions in solution to create an electric 
double layer.  When voltage is applied across the capillary, the positively charged ions migrate 
towards the negative pole.  These cations associated with the electric double layer interact with 
other components of the buffer through hydrogen-bonding and electrostatic interactions, and 
within the narrow confines of the capillary these interactions are strong enough to cause bulk 
migration of the buffer flow.  This results in consistent flow towards the detector with a nearly 
flat fluidic profile that sweeps all analytes towards the detector.  Depending on its strength, this 
can allow the detection of neutral or even negatively charged species.  CE can be coupled with 
laser-induced fluorescence detection (LIF), allowing for detection of fluorescent analytes at 
extremely low concentrations (10-21 moles).23  The high resolving power and small sample 
requirements (< 10 nL) of CE, paired with the high sensitivity of LIF, makes it an ideal 
technique for the analysis of small numbers of cells, including single cells.23, 25, 26 
1.7 Scope of the Research 
This dissertation details the development of novel peptide reporters for the measurement of 
E3 ligase activity via chemical cytometry.  Chapter two focuses on the early development of a 
library of E3 ligase reporters incorporating degrons from various sources in order to identify, 
characterize, and optimize substrates that would be efficiently ubiquitinated in cells.  This work 
has been published in both Cell Biochemistry and Biophysics and PLOS ONE.30, 31  Chapter 
three details the creation of a sub-library of reporters around the degron isolated from p53.  This 
work both identified a minimal degron element and investigated its ubiquitination kinetics and 
specificity.  The results of this work were reported on in the Analyst.32   Chapter four focuses on 
the characterization of novel degradation-resistant E3 ligase reporters with β-hairpin secondary 
structures.  This work has been submitted to ACS Chemical Biology for publication.  Finally, 
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chapter five presents unpublished work that lays the groundwork for analysis of E3 ligase 
peptide reporters by CE. 
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1.8 Figures 
 
Figure 1.1   A simplified overview of the ubiquitin proteasome system (UPS).  Ubiquitin is 
activated by an E1 activating enzyme and transferred to an E2 conjugating enzyme.  This 
complex then interacts with an E3 ligase, which recognizes targeted proteins and facilitates the 
conjugation of ubiquitin to a proximal lysine.  The conjugated ubiquitin can have further 
ubiquitin molecules added to, forming a poly-ubiquitin chain.  This poly-ubiquitin chain is 
recognized by the 19S regulatory element of the proteasome, which unfolds the protein into the 
catalytic core, resulting in the degradation of the protein.  Deubiquitinating enzymes (DUBs), 
including those on the 19S regulatory element of the proteasome, can cleave ubiquitin from a 
protein, allowing it to be recycled by the cell.  
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Figure 1.2 Limitations of current analytical techniques for measuring E3 ligase activity.  
Current popular techniques do not encompass the requirements for the analysis of patient 
samples.  Western blots are the most popular form of analysis, but require large sample sizes and 
do not directly measure enzymatic activity.  RT-PCR is compatible with small sample sizes, but 
measures levels mRNA, a proxy twice removed from ubiquitination.  FRET-based reporters 
directly measure E3 ligase activity, but require genetic engineering approaches, requiring large 
initial numbers of cells and long development times. 
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Figure 1.3 General design of peptide reporters. Reporters consist of three key elements: (1) an 
E3 binding recognition site (degron), (2) a proximal lysine residue for ubiquitin conjugation, and 
(3) a fluorescent tag for detection and quantification.  Additionally (4), an optional spacer 
element, can be included to modulate reporter length for optimal posting of the proximal lysine.   
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Chapter 2: Generating a Degron Reporter Library 
2.1 Introduction 
The ubiquitin proteasome system (UPS) is a key enzymatic pathway that plays a central role 
in cell homeostasis.1, 2  The UPS is composed of a constellation of enzymes with diverse 
functions, which are collectively responsible for the degradation of misfolded and damaged 
proteins.  This process is regulated through the post translation modification of proteins by 
ubiquitin (i.e., ubiquitination), which, in addition to its role in the degradation of proteins plays 
an important role in DNA repair, cell cycle regulation, and immune responses.  The UPS is 
comprised of several enzyme families: Ubiquitin, E1 and E2 enzymes, and the E3 ligase. 
Ubiquitin is a small, 76 amino acid protein found throughout the cell and primarily functions to 
post translationally modify UPS-targeted proteins. E1 ubiquitin-activating enzymes chemically 
activate ubiquitin in a process consuming adenosine triphosphate (ATP) to chemically activate 
ubiquitin, which is then accepted by E2 ubiquitin-conjugating enzymes. Finally, E3 ligases 
interact with the E2-ubiqutin complex and facilitate the process of conjugating the activated 
ubiquitin to an available lysine residue on a targeted protein.  Either the E3 ligases bring E2 
enzymes and substrates together or they act as an intermediary for the activated ubiquitin to 
accomplish the conjugation.  Additionally, E3 ligases recognize proteins through specific 
degradation signals, or degrons, on target protein substrates.3  These substrates can be simple 
amino acid sequences, or more complex, requiring post translation modifications such as 
phosphorylation or oxidation. The E3 ligase is primarily responsible for the tightly controlled 
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regulation of the UPS; they are a highly diverse class of enzymes comprised of over 600 proteins 
in humans. 
Following an initial ubiquitination event, the conjugated ubiquitin protein can accommodate 
further ubiquitin conjugations via one of its seven lysine residues.  The number and subsequent 
position of ubiquitin molecules determine the signaling properties of the attached ubiquitin 
moieties.4  For instance, ubiquitin chains (i.e., poly-ubiquitin) formed at the 48th position lysine 
residue target proteins to be sent to the 26S proteasome for degradation.5  The 26S proteasome is 
a large protein complex that recognizes poly-ubiquitin, then unfolds and threads a targeted 
protein into its catalytic core, where it is subsequently degraded into small peptide fragments.  
Acting in opposition to E3 ligases are deubiquitinating enzymes (DUBs), which selectively 
cleave the conjugated ubiquitin from a protein, potentially rescuing it from degradation and 
allowing ubiquitin to be removed from a protein prior to degradation. 
Dysregulation of the E3 ligases in particular has been observed in a number of diseases, 
including several cancers.6-9  Drugs that target elements of the UPS, such as the proteasome 
inhibitor Bortezomib and the second generation Carfilzomib, have found clinical success treating 
multiple myeloma, demonstrating that components of the UPS are excellent candidates for 
targeted therapeutics.7, 10  Dysregulation of the E3 ligases in particular has been observed in a 
number of diseases, including several cancers.6-9  While there is intense interest in the research 
community to investigate components of the UPS, current analytical tools used to probe the 
enzymatic activity of these components leave much to be desired.1 
Several technologies including Western blots, qPCR (quantitative polymerase chain 
reaction), FRET (Förster resonance energy transfer) sensors, and proteomic approaches such as 
SILAC (stable isotope labeling with amino acids in cell culture) are used widely in the literature; 
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however, each have drawbacks that make them problematic for investigations into primary cell 
samples: They either probe enzymatic activity indirectly, require genetic engineering, or require 
large numbers of cells and thus only provide bulk analyses.11-19  Chemical cytometry overcomes 
these limitations by using peptide-based reporters as substrates for enzymes of interest, making it 
an attractive alternative analytical strategy.20  This strategy revolves around the use of peptide 
based reporters that act as substrates for enzymes of interest.  These reporters can be introduced 
into cells or cell lysates, where they are recognized by select enzymes and undergo post-
translational modifications, (e.g., phosphorylation).21-24  The reporters can be conjugated to a 
fluorescent tag such as fluorescein, allowing highly sensitive laser induced fluorescence (LIF) 
detection to be used.  This, when paired with the extremely small sample size requirements, 
exceptional separation efficiency, and peak capacity of capillary electrophoresis (CE), can detect 
enzymatic activity in samples as small as single cells.  Through well-established solid phase 
peptide synthesis (SPPS), peptides can be rapidly synthesized and prototyped, by passing genetic 
engineering requirements, and peptides measure rates of post-translational modification, 
allowing for direct measures of enzymatic activity.   
Given the importance of E3 ligases in regulating and facilitating protein ubiquitination, their 
penultimate position in the UPS, and their observed dysregulation in several diseases, they 
present an excellent target for new peptide reporter technologies.  Peptide reporters require three 
key components in order to investigate E3 ligase ubiquitination kinetics: (1) a degron for E3 
ligase recognition, (2) an available lysine residue for ubiquitination, and (3) a fluorescent tag for 
detection (Figure 2.1A).  We also speculate that a fourth element, a spacer, might be required to 
prevent steric hindrance between elements of the reporter.  This work describes the development 
of a small library of nine reporters that contain elements from both natural and artificial sources, 
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to determine an optimal substrate for measuring ubiquitination.1, 25  Particular interest was paid to 
the formation of poly-ubiquitin chains versus multiple mono-ubiquitination events.  An 
additional library of iterations of the top performing initial reporters were synthesized to 
investigate the effect of the spacer element and determine the position of the most rapidly 
ubiquitinated lysine residue.  Additionally, a computational model was developed to quantitate 
and describe the ubiquitination process.  
2.1.1 Initial Selection of Reporter Library and Reporter Design 
Initially, nine degrons were selected by Dr. Adam Melvin and Dr. Kaiulani Houston for their 
potential use as an E3 ligase reporter.26-35  The origin and sequence of each degron used in the 
initial reporter library are listed in Table 2.1, along with the E3 ligases known to recognize them. 
These selected peptides were the result of an extensive literature search, and come from several 
representative classes of degrons, including degrons that require phosphorylation prior to 
recognition by E3 ligases (TAZ, IFNAR1, SRC3, and Cyclin D1), and degrons that are oxidation 
dependent (HIF-1α).  Degrons were also pulled from a number of different sources including: 
tumor suppressors (p53), proteins that are key to cell homeostasis (iNOS, β-Catenin), and 
artificial sources (Bonger).26-36  
All degrons were next incorporated into a standard design for peptide reporters.  Each 
peptide reporter consisted of a degron, an N-terminal lysine, and a C-terminal fluorescent tag.  
Because the degrons pulled from the literature had highly variable sequence lengths that ranged 
from as few as four amino acids (Bonger) to as many as 25 (p53), spacer elements were 
incorporated to standardize the size of the initial reporters and minimize steric effects between 
reporter elements.  Reporters containing small degron sequences were extended to approximately 
25 amino acids using protein sequences from the NCBI database.  In the event that the degron 
22 
 
sequence did not contain a lysine proximal to the degron, as was the case for iNOS and SRC3, 
we incorporated polyethylene glycol (PEG) into the reporter to provide functional distance 
between the degron and lysine residue.  During the initial round of synthesis, a triple lysine C-
terminus was designed into each peptide to provide net positive charge and thus promote peptide 
solubility in aqueous solution, and also to minimize steric interactions between the fluorescein 
tag and amide resin during synthesis. 
2.2 Experimental Design 
2.2.1 Peptide Reporter Synthesis 
All reporters were synthesized using SPPS, either manually or with an automated synthesizer 
(Creosalus TetrasUI Peptide Synthesizer, Louisville, KY).  Synthesis was carried by Dr. Adam 
Melvin, Dr. Kaiulani Houston, and Gregery Woss, with the Waters laboratory providing 
expertise and guidance.  Peptide synthesis was performed on CLEARamide resin beads (Peptides 
International Louisville, KY), using Fmoc-[N]-protected amino acids purchased from Advanced 
Chem Tech (Louisville, Kentucky). The Fmoc-[N]-protected unnatural amino acids Fmoc-NH-
(PEG)-COOH, Fmoc-Ser[PO(OBzl)-OH]-OH, Fmoc-Thr[PO(OBzl)-OH]-OH, and Fmoc-
Lys(ivDde)-OH were purchased from EMD Biosciences (Billerica, MA). 5,6-carboxyfluorescein 
acquired from Sigma (Saint Louis, MO) was used to fluorescently tag peptides. 
Fmoc deprotection was carried out by gently agitating beads in a DMF (dimethylformamide) 
solution containing 2% piperidine and 2% DBU (1,8-diazobicyclie[5.4.0]undec-7-ene).  
Deprotection was carried out twice over the course of 15 minutes.  For peptides containing 
aspartate residues, an alternative deprotection solution containing 20% piperidine and 0.1 M 
HOBt (hydroxybenzotriazole) in DMF was used.  Amino acid activation was carried out in a 
solution of NMP (N-methyl-2-pyrrolidone) containing four equivalents of HBTU (2-(1H-
benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexaﬂuorophosphate), four equivalents of HOBt, 
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and five equivalents of DIPEA (N,N-diisopropylethylamine).  Amino acid coupling was carried 
out twice for 30-60 minutes each.  To conserve regents, unnatural amino acids were coupled in a 
single reaction over the course of four hours using five equivalents of the unnatural peptide and 
four equivalents of HBTU, HOBt, and DIPEA. 
Following the addition of the final amino acid, peptides had their N-terminus acetylated.  
This was accomplished by reacting the peptide with 5% acetic anhydride and 6% 2,6-lutidine in 
DMF for 35 minutes.  Next, the ivDde protecting group was removed to allow for conjugation of 
the fluorescent tag.  This was done by mixing the peptide with a solution of 3% anhydrous 
hydrazine in DMF for three minutes three times.  A Kaiser test confirmed the ivDde group 
removal.  To conjugate the peptide and fluorescent tag, four equivalents of 5,6-
carboxyfluorescein and four equivalents of HOBt and PyBOP (benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate) were mixed in DMF overnight in the dark.  
Finally, peptide was cleaved from the resin using a mixture of 95% TFA (trifluoroacetic acid), 
2.5% TIPS (triisopropylsilyl) and 2.5% water for 3 hours.  Excess TFA was evaporated under a 
steady flow of nitrogen, and cleavage products were precipitated into ice cold ether.  This mix 
was extracted into water, lyophilized, and stored at -4°C until purification.  
Following synthesis, all peptides were purified using reverse phase HPLC on an Atlantis C-
18 semi-preparative column (Waters, Morrisville, NC).  Purification was carried out by either 
Dr. Melvin or Gregery Woss.  Peptides were first purified using a 60-minute gradient from 95% 
acetonitrile, 5% H2O and 0.1% TFA to 95% H2O, 5% acetonitrile, and 0.1% TFA.  Peptide 
masses were verified using MALDI (matrix-assisted laser desorption/ionization) mass 
spectrometry.   Following verification of peptide mass, the peptides were lyophilized and then 
purified a second time using the same gradient as above but extended to a 100-minute duration.  
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After purification, peptides were suspended in 50 mM phosphate buffer (pH 8.0) and quantified 
using a Nanodrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA) at the 5,6-
carboxyfluorescein tag absorbance wavelength, 492 nm.  Peptides were aliquoted and stored at -
20 °C. 
2.2.2 Generation of HeLa S100 Lysates and Cell Cultures 
To ensure a consistent and potent source of UPS components, HeLa S100 lysates were 
generated and frozen for use throughout the peptide library development process.  HeLa S100 
lysates were generated by either Dr. Adam Melvin or Gregery Woss.  HeLa S3 cells (ATCC 
Manassas, VA) were initially grown in Dulbecco’s modified eagle medium (DMEM) 
supplemented with 10% v/v bovine calf serum (HyClone, GE Healthcare Logan UT) and 
maintained in a 37 °C, 5% CO2 environment.  Following initial thaw, cells were grown in T-75 
culture flasks until they reached 70% confluence.  Following this, cells were rinsed with PBS 
and treated with 2 mL trypsin-EDTA for five minutes or until detached, at which point they were 
transferred to a centrifuge tube and spun at 800g for 10 minutes.  Media was discarded and cells 
were resuspended in fresh media and expanded into additional flasks.  This process continued 
until eight flasks reached 70% confluence.  Cells were then pooled together, the media was 
discarded, and the cells were resuspended in suspension growth media (Roswell Park Memorial 
Institute (RPMI) 1640 media supplemented with 5% v/v bovine calf serum) to a density of 2 x 
105 cells/mL in a 250 mL spinner flask.  Cells were monitored closely and fresh media was 
added daily to maintain a cell density of 2 x 105 and 5 x 105 cells/mL.  Once media volume 
exceeded 250 mL, cells were spun down at 800g for 10 min and resuspended in fresh media in a 
1 L spinner flask at a density of 2 x 105 cells/mL.  This process was repeated until the suspension 
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volume reached 1 L, at which point the above process was repeated and the cells transferred to a 
3 L spinner flask.   
Cells were allowed to grow with fresh media being added periodically until the suspension 
reached a volume of 3 L and a density of 4-6 x 105 cells/mL.  The media was removed and cells 
were washed in ice cold PBS.  Cells were spun at 1200g for 10 minutes at 4 °C.  The resulting 
pellet volume was recorded as packed cell volume (PCV). PBS supernatant was removed from 
the cells and replaced with 5 x PCV hypotonic buffer (10 mM HEPES, pH 8.0, 10 mM KCl, 1.5 
mM MgCl2, and 1 mM DTT), which caused the cells to swell over 10 minutes at 4 °C.  Cells 
were spun at 1800g for 10 minutes at 4 °C and the hypotonic buffer was removed.  Cells were 
resuspended in 2 x PCV hypotonic buffer and lysed using approximately 10 strokes of a Dounce 
glass homogenizer.  The resulting lysate was centrifuged for 10 minutes at 1200g, at which point 
the resulting supernatant was collected and supplemented with 0.11 x PCV of buffer B (0.3 M 
HEPES, pH 8.0, 1.4 M KCl,and 30 mM MgCl2).  The resulting lysates were placed in an ultra-
centrifuge and spun at 100,000g for 60 minutes at 4 °C. The cytosolic supernatant was collected 
and dialyzed twice in buffer D (20 mM HEPES, pH 8.0, 100 mM KCl, 0.2 mM EDTA, 0.5 mM 
PMSF, 1 mM DTT, and 20% v/v glycerol) at 4 °C, first overnight and then again for four hours.  
The reduced lysate was centrifuged one final time at 33,000g for 20 minutes at 4 °C to remove 
membrane proteins.  The cytosolic lysates were quantified using a Nanodrop 2000, aliquoted, 
and stored at -80 °C. 
For studies using other cell lines, fresh cell lysates were prepared shortly before each 
experiment.  HeLa, HL-60, THP-1, and U937 cells were all acquired from the Lineberger Tissue 
Culture Facility at the University of North Carolina at Chapel Hill. HeLa cells were grown in 
DMEM with 10% v/v fetal bovine serum (FBS, Atlanta Biologics, Flowery Branch, GA). THP-1 
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cells were grown in RPMI 1640 supplemented with 10% v/v FBS and 0.05 mM 2-
mercaptoethanol. U937 cells were cultured in RPMI 1640 with 10% v/v FBS. HL-60 cells were 
grown in RPMI 1640 with 10% v/v FBS and 1% v/v penicillin-streptomycin. 
2.2.3 In Vitro Ubiquitination Assay 
Peptide performance was measured using an in vitro ubiquitination assay using HeLa 
S100 lysates as the source of UPS components.  In vitro ubiquitination assays were carried out 
by Dr. Adam Melvin or Gregery Woss.  The reaction was carried out in 20 μL of a reaction 
buffer consisting of 10 mM Tris-HCl, pH 7.6, 5 mM MgCl2, and 2 mM DTT.  This buffer was 
supplemented with 1 x ATP energy regenerating solution (ATP-ERS, Boston Biochem, 
Cambridge, MA), 100 mM of the proteasome inhibitor MG-132 (EMD Chemicals Billerica, 
MA), 20 mg/mL ubiquitin aldehyde (Boston Biochem, Cambridge, MA), 400 mg/mL ubiquitin 
or methylated ubiquitin (Enzo Life Sciences Farmingdale, NY), and 750 ng of inhibitors 
cOmplete ULTRA and PhosSTOP (Roche). HeLa S100 (2 mg/mL) lysates were thawed and 
immediately added to this reaction mixture prior to the experiment.  The reaction was initiated 
with the addition of 750 ng of peptide, and the sample was incubated at 37 °C for a set period of 
time.  The reaction was halted with the addition of 40 μL tricine sample buffer (Bio-Rad, 
Hercules, California) followed by boiling for 5 minutes.  
2.2.4 Ubiquitin Pull Down Assay 
In order to validate ubiquitination of peptide reporters, pull down experiments using 
agarose beads coated in ubiquitin antibodies were employed.  Pull down experiments were 
carried out by either Dr. Melvin or Gregery Woss. The reaction buffer described in the previous 
section was prepared using 5x the original reaction volume (100 μL) while keeping the reagent 
concentrations constant. Pulldown reagents were prepared immediately prior to use.  For each 
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sample, 20 μL of Control-Agarose bead slurry (LifeSensors Malvern, Pennsylvania) and 25 μL 
Agarose-TUBES1 slurry (Tandem Ubiquitin Binding Entity, LifeSensors Malvern, 
Pennsylvania) were thawed on ice and suspended in 1 mL of ice cold TBS-T (20 mM Tris-HCl, 
pH 8.0, 150 mM NaCl, and 0.1% v/v Tween-20) and centrifuged at 1800g for 5 minutes at 4 °C. 
The TBS-T was removed from the bead pellet and discarded, then the beads were suspended in 1 
mL of fresh TBS-T.  This process was repeated for a total of 5 washes, after which beads were 
suspended in 100 μL of fresh TBS-T. 
 Following incubation of the reaction buffer, 300 μL of TBS-T was added to halt the 
reaction. Then, agarose control beads were added.  The sample was then transferred to a tube 
rotator and incubated for 1 hour at 4 °C.  Samples were centrifuged at 1800g for 5 min to pellet 
the control beads and the sample supernatant was transferred to a fresh centrifuge tube.  Agarose-
TUBES1 beads were added to the sample, and the sample was returned to the tube rotator and 
incubated overnight at 4 °C.  Samples were centrifuged at 1800g, the supernatant discarded, and 
the beads suspended in 1 mL of TBS-T.  This process was repeated five times to rinse away non-
specifically adsorbed analytes.  Following the final wash, beads were suspended in 50 μL tricine 
sample buffer and heated at 90 °C for five minutes to elute any analytes bound to the bead.  
Samples were centrifuged for 5 min at 13000g, and the resulting supernatant collected.  Samples 
were either immediately analyzed or kept at -20 °C until analysis. 
2.2.5 Ubiquitination Assays Carried out in Cell Lysates 
Ubiquitination assays in cell lysates were carried out using the same protocol as the in 
vitro ubiquitination pull downs, with the major exception being the substitution of freshly 
prepared cell lysates for HeLa S100 lysates, with a final lysate protein concentration of 2 
mg/mL.  Ubiquitination assays in cell lysates were performed by either Dr. Melvin or Gregery 
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Woss.  Lysates were prepared from tissue cultured cell lines immediately prior to the assay.  
Once cells had reached the appropriate confluence or cell density, cells were centrifuged at 800g 
for 2 minutes, and washed twice in PBS.  Cells were pelleted and re-suspended in approximately 
1 x cell pellet volume using MPER lysis buffer (Mammalian Protein Extraction Reagent, Fisher, 
Hampton, NH).  This was vortexed at 900 RPM for 10 minutes at 25 °C, then centrifuged at 4 °C 
for 15 minutes at 14,000 x g.  The resulting supernatant was collected and its protein 
concentration was quantified using an M5 spectrophotometer (Molecular Devices, Sunnyvale, 
California).  The sample was stored on ice until use.  
2.2.5 SDS-PAGE Analysis 
Samples were separated using SDS-PAGE and analyzed using fluorescence imaging.  
SDS-PAGE analysis was carried out by either Dr. Melvin or Gregery Woss.  Samples were 
loaded into precast 16.5% Mini PROTEAN Tris-Tricine (Bio-Rad Hercules, CA) using 20 μL of 
sample per well.  The gel was subjected to a 120 V differential until tricine buffer bands reached 
the bottom of the gel.  Benchmark fluorescent ladder (ThermoFisher, Waltham, MA) was 
included in all gels as a standard to estimate molecular weight of analytes.  Gels were visualized 
using a Typhoon Imager (GE Healthcare Life Sciences, Pittsburgh, PA) at the highest sensitivity 
possible without saturating the detector. Gels were quantified using ImageJ software (US 
National Institute of Health), and measured sample band intensity relative to the unreacted parent 
peptide band intensity. 
2.2.6 Data Analysis 
Dr. Adam Melvin was primarily responsible for the development of computational 
models. Data was analyzed using Origin 7.0 (OriginLab), equations were solved in MATLAB 
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using ODE15s.  Additional information about the mathematical model used can be found in 
reference 25. 
2.3 Results and Discussion 
An initial library of nine reporters was initially synthesized using SPPS, then purified by two 
rounds of reverse phase HPLC.  The molecular weight of the reporter was verified following 
purification using MALDI-TOF, after which it was reconstituted into 50 mM phosphate buffer 
(pH 8.0). Reporter concentrations were quantified using absorbance measurements.  The peptides 
were stored at -20 °C until use.   
While developing and evaluating the peptide library, it was key to have a potent and 
consistent source of UPS components.  Cell lysates provided an excellent source of these 
components, as they contain a multitude of E1, E2, and E3 enzymes, enabling ubiquitination of 
peptides even with unknown E3 ligases.  Due to cell heterogeneity, it was vital to prepare a large 
batch of lysates to perform separate ubiquitination experiments under reproducible conditions.  
To this end, HeLa S100 cytosolic lysates were selected as a source of UPS components.  These 
lysates contain a litany of concentrated cytosolic enzymes, and could be prepared in large 
batches and frozen until use. 
For ubiquitination experiments, HeLa S100 lysates were mixed with buffering reagents and 
supplemented with MgCl2, ATP, and inhibitors for peptidases, phosphatases, and the 
proteasome.  Excess ubiquitin was also added to the reaction buffer, either in the form of wild 
type ubiquitin or methylated ubiquitin (MeUb).  MeUb was chosen to probe mono-ubiquitination 
event kinetics because each of its lysine residues is blocked by methyl group; thus, MeUb is 
incapable of forming poly-ubiquitin chains.   
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Each of the nine initial reporters were evaluated in a time course assay and analyzed using 
SDS-PAGE (examples shown in Figure 2.2).  Early work was done by Dr. Adam Melvin and Dr 
Kaiulani Houston, with Gregery Woss joining the project after initial synthesis and evaluation of 
several reporters.   The fluorescent tag allowed for easy and sensitive detection of analytes 
without the need for antibodies.  All nine initial reporters demonstrated an increase in 
ubiquitination over time, as expected; however, formation of ubiquitinated products differed 
between reporters, with some reporters producing more intense ubiquitination bands than others.  
Analysis also showed the formation of a low molecular weight band over time, attributed to the 
degradation of the parent peptide over time, which was expected even with the addition of 
peptidase inhibitor. 
Of particular note was that the incorporation of MeUb into the assay did not always result in 
the formation of a single ubiquitination band (Figure 2.2D).  This result strongly indicated that 
either multiple mono-ubiquitination events occurred at several of the reporter’s lysine residues 
(multi-mono-ubiquitination), or that endogenous ubiquitin from the HeLa S100 was 
incorporated, contributing to a poly-ubiquitin chain.  The latter was considered unlikely, as 
MeUb was calculated to exceed endogenous ubiquitin by a factor of 100 or more.37 
In order to further validate that the ubiquitinated peptide accounted for the observed high 
molecular weight bands, an antibody-based pull down assay was carried out.  Following the 
previously described ubiquitination reaction, samples were incubated with agarose beads coated 
in ubiquitin-specific antibodies.  This allowed for the collection of only analytes containing an 
ubiquitin moiety, providing excellent supporting evidence that the observed bands were 
ubiquitinated reporter.  As an additional benefit, the antibody pulldown also allowed for the 
concentration of ubiquitinated analytes (Figure 2.3). 
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2.3.1 Initial Comparison of Degron Ubiquitination Rates 
All nine developed peptide reporters demonstrated time-dependent ubiquitination.  In 
order to compare performance between reporters, the intensity of each band was normalized to 
the band intensity of an unmodified peptide that was not subjected to the ubiquitination assay. 
Within the nine peptide reporters surveyed, there was a high degree of variability in the 
formation rate of high molecular weight bands, demonstrating the importance of the degron 
component.  Four of the initial reporters, Bonger, p53, and iNOS, and β-Catenin, showed 
particularly rapid ubiquitination kinetics, especially compared to the other five reporters (Table 
2.2).  Initial studies indicated that the reporter incorporating the degron from p53 was most 
rapidly ubiquitinated, and close inspection of the results revealed the presence of bands 
correlating to di-, tri-, and tetra-ubiquitination events (~21, ~30, and 39 kDa) in addition to 
mono-ubiquitination events.  The origin of these bands were likely multi-mono-ubiquitination 
events, as the ratio of added MeUb was calculated to be in large excess of endogenous wild type 
ubiquitin (>100 times).37  While this result was initially unexpected, it can be explained by the 
presence of multiple lysine residues on each reporter, either in the original degron sequence or as 
part of the triple lysine C-terminus added to aid in synthesis.   
2.3.2 Effects of Degron Size and Lysine Position on Ubiquitin Rate 
The next step in the reporter library development was to further refine the top reporters 
by investigating the effects of both the reporter size and the position of the most rapidly 
ubiquitinated lysine residue.  Initially, all reporters were standardized in length (~25 amino 
acids); however, it was unclear if the additional residues were required or if they affected 
ubiquitination rates.  For Bonger, iNOS, and β-Catenin peptides, a smaller minimal degron had 
been reported, whereas the minimal degron size for p53 was unknown.26, 30, 35  Additionally, 
while the presence of multiple lysine residues could potentially enhance the overall 
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ubiquitination rate, multiple ubiquitination sites can confound kinetic analysis by convoluting 
poly- and multi-mono-ubiquitination events. To detect poly-ubiquitination chains is desirable not 
only because it could deconvolute kinetic measurements, but also because poly-ubiquitin chains 
serve as the recognition element for the 19S regulatory particle of the 26S proteasome.  To 
investigate these effects, four reporter sub-libraries were synthesized using the top four 
preforming peptides (p53, Bonger, iNOS, and β-Catenin). 
 Initial work was done using β-Catenin, which performed well in early trials.  The β-
Catenin reporter initially incorporated a phosphorylated serine into the degron component, but 
during the design of the expanded library, this residue was substituted with phosphomimetic 
glutamic acid, which prevents dephosphorylation during a ubiquitination reaction.  The 
substitution did not appear to have an effect on the ubiquitination rate (Figure 2.4D).  Continued 
work proceeded to examine the effect of peptide length on ubiquitination rate, as work by Wu et 
al. had previously established the importance of the spacing between lysine residues and β-
Catenin’s minimal degron element.35  A shortened β-Catenin was synthesized using the minimal 
degron element DEGIHEG; however, this version of the reporter exhibited markedly decreased 
ubiquitination kinetics (Figure 2.4D, lane 3).  Given this finding, it is highly likely that the spacer 
amino acids play an important structural role in the ubiquitination of β-Catenin. 
 Following peptide length studies, we investigated the position of the most rapidly 
ubiquitinated lysine residue.  Five additional variants of the reporter were synthesized, three full 
length versions and two shortened ones, with all but a single lysine residue substituted for either 
valine on the N-terminus or arginine on the C-terminus.  The results demonstrate a clear and 
pronounced preference for a lysine residue on the C-terminal side of the full length peptide 
(Figure 2.4D lanes 4-8).  Moving the lysine residue a single position away from the C-terminus 
33 
 
slightly decreased ubiquitination, but not as much as having an N-terminal lysine.  Both 
shortened reporters had comparable and significantly reduced ubiquitin kinetics.    
Similar to β-Catenin, development of the Bonger reporter focused on the importance of the 
proximal distance between the portable degron (RRRG) and the ubiquitination site.  Three 
variants of the reporter were synthesized, beginning with a compact, nine amino acid variant 
(KRRRGK(FAM)KKK), as well as two variants incorporating PEG monomers: 
(K(PEG)RRRGK(FAM)KKK) and (K(PEG)2 RRRGK(FAM)KKK).  The triple lysine C-
terminus was left in place to investigate degron size, but it also had an effect on poly-
ubiquitination versus multi-mono-ubiquitination.  The modified reporters were compared to the 
initial ‘full sized’ reporter (KTRGVEEVAEGVVLLRRRGNK(FAM)KKK) used in the initial 
screening process using a pull-down assay incorporating MeUb (Figure 2.4A, lanes 1-3).  These 
results demonstrated that the Bonger based reporter only required the compact degron for 
ubiquitination, and that removing the spacing element did not negatively impact the 
ubiquitination rate.  Additionally, we determined that the length of the reporter did not appear to 
play a role in the formation of multi-mono-ubiquitination. 
Next, the preferential ubiquitination site was isolated.  This was done by synthesizing 
variants of the reporter using either a triple arginine or triple glycine C-terminus.  Both of these 
variants demonstrated marked decreases in ubiquitin band intensity, suggesting the preferential 
ubiquitination site was likely on the C-terminus (Figure 2.4A, lanes 4,5).  This finding 
corresponded well with reports in the literature about the Bonger peptide.  A new variant was 
synthesized that incorporated a single lysine residue on the C-terminus (VRRRGK(FAM)GGK); 
valine was chosen to replace lysine on the N-terminus in an effort to increase stability based on 
the N-end rule.38  This new variant produced increased ubiquitin band intensity relative to that of 
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peptide reporters with only an N-terminal lysine, suggesting that the C-terminus lysine was 
preferentially ubiquitinated (Figure 2.4A lane 6).   
A similar sub-library was generated for iNOS based around its portable degron (DINN).  
Similar to β-Catenin, removing the amino acid spacing elements significantly decreased the rate 
of ubiquitination (Figure 2.4B, lanes 1,2).  Integrating a PEG spacer element did not recover the 
ubiquitination rate, suggesting that the amino acid spacer element may play an important role in 
enhancing ubiquitination rates, perhaps through an interaction with an E3 ligase.  Further 
experiments demonstrated that the replacement of the triple lysine C-terminus with a triple 
arginine sequence did not further reduce the rate of ubiquitination, suggesting that the N-
terminus contained the preferential ubiquitination site (Figure 2.4B, lane 3). 
Refining the reporter containing the p53 degron was less straightforward because its portable 
degron was unknown.  Because of this uncertainty, the site of the preferentially ubiquitinated 
lysine was first investigated.  Variants of the p53 reporter where available lysine residues only 
presented on the N- or C-termini yielded similar results, which, paired with the presence of di-
ubiquitin, suggested that a lysine residue in the degron sequence might be contributing to the rate 
of ubiquitination (Figure 2.4C, lanes 1,2).  To test this hypothesis, a second set of peptides were 
synthesized with a single available lysine residue, either on the N-terminus or in the middle of 
the peptide.  Both variants produced similar amounts of ubiquitination, with the N-terminal 
lysine variant demonstrating slightly faster kinetics.  These results suggested that having a free 
lysine residue available in the reporter was sufficient for ubiquitination (Figure 2.4C, lanes 3,4).  
Once it was determined that no single free lysine was preferentially ubiquitinated, work was 
done to identify whether a degron sequence could be truncated without compromising the 
reporter ubiquitination rate.  This was done by synthesizing three reporters (N-terminal, a middle 
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segment, and a C-terminal) using a shortened sequence selected at random (~9-10 amino acids).  
While all three reporters demonstrated ubiquitination, the peptide incorporating the middle 
segment performed best.  These results suggest the previously reported portable degron for p53 
might be further reduced and refined (Figure 2.4C, lanes 5-8).  
In order to investigate whether reporter optimization had an impact on poly-ubiquitination, a 
final set of experiments was carried out with the optimized substrates for β-Catenin, Bonger, 
iNOS, and p53, using wild type recombinant ubiquitin (Figure 2.5).  Each peptide reporter 
contained either a one (Bonger, iNOS, β-Catenin) or two (p53) free lysine residues, and upon 
analysis demonstrated the characteristic poly-ubiquitin ladder formation indicative of tetra-
ubiquitin plus chain lengths. 
2.3.3 Performance of Reporters in Different Cell Lines and In Vitro Ubiquitination Assay  
The initial peptide library screen identified and optimized four top-performing peptide 
reporters incorporating degrons from Bonger, p53, iNOS, and β-Catenin.  The next step in 
reporter development was to validate their performance outside of HeLa S100 lysates (i.e., in 
freshly prepared cell lysates), and to examine how they were affected by variable E3 ligase 
compositions and concentrations.  HeLa S100 lysates used in the reporter development presented 
a potent and reproducible source of UPS associated enzymes, but only allowed investigation into 
a single, artificial cellular environment containing a fixed concentration of only cytosolic 
enzymes. Additionally, it was unknown what the effect of reporter optimization had on E3 ligase 
specificity.  In order to investigate these effects, four cell lines were selected to investigate 
peptide performance: HeLa (adenocarcinoma), U937 (histiocytic lymphoma), THP-1 (acute 
monocytic leukemia), and HL-60 (acute promyelocytic leukemia).  These assays were carried out 
in a similar fashion to those used in the HeLa S100 studies, with the substitution of freshly 
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prepared lysates and the addition of recombinant wild-type ubiquitin.  While the precise 
concentration and composition of UPS components of each cell line was unknown, it was 
assumed that there would be variability between cell lines. This hypothesis appears to be 
supported by the results: HeLa lysates produced markedly similar results to those of the HeLa 
S100 lysates, as did U937 lysates.  However, THP-1 and HL-60 lysates produced substantially 
diminished rates of ubiquitination, potentially indicating variability in UPS-associated enzymes 
between cells of different disease states (Figure 2.6A). 
In order to investigate the specificity of the optimized p53 based reporter, experiments were 
carried out using a cell-free in vitro assay.  The p53 reporter was incubated with recombinant E1, 
E2, and Hdm2 enzymes in the presence of ATP` and ubiquitin.  When all components were 
present, the reporter was ubiquitinated; however, excluding either E1 or E2 enzymes prevented 
the reaction from proceeding.  In contrast, while the absence of Hdm2 did affect the 
ubiquitination rate, it did not prevent ubiquitination. This indicated that Hdm2 was no longer 
essential for ubiquitination and suggested that the reporter was no longer specific to Hdm2 
(Figure 2.6B, lanes 1-4).  Follow-up studies using the Hdm2 inhibitors HLI-373 and NSC-66811 
provided additional evidence supporting this idea, as neither drug prevented reporter 
ubiquitination.  It should be noted that a high dose of NSC-66811 (1 μM) did reduce the 
ubiquitination rate, though it is unclear whether this is an effect of Hdm2 activity loss or a non-
specific effect of the inhibitor. (Figure 2.6B, lanes 5-8) 
2.3.4 Computational Modeling of Ubiquitination Rates 
Kinetic analysis was computationally modeled by Dr. Adam Melvin using the generated 
peptide library; however, it warrants discussion as it informed further development of the 
reporter library.  The goals of the kinetic model were to describe the ubiquitination process in a 
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stepwise function, ultimately determining the kinetics of ubiquitin conjugation to the peptide 
reporter.  This model relied on first order kinetics to account for the addition of ubiquitin (both 
poly- and multi-mono events) as well as the degradation of ubiquitinated products.  The model 
uses a Markov Chain Monte Carlo algorithm to fit the data collected from pulldown experiments 
using both wild-type and methylated ubiquitin (Figure 2.7).  Based on these results, approximate 
rate constants for all nine reporters in the initial library screen were obtained (Table 2.2). 
2.4 Conclusions 
A library of nine novel peptide reporters that incorporated degrons from several sources 
were synthesized and analyzed using an in vitro cell-based assay.  This work ultimately 
identified four candidate reporters for future development based on ubiquitination rates versus 
peptidase-mediated degradation.  With growing interest in the UPS and the role it plays in 
disease, these reporters serve as the groundwork for a new technology to fill a current gap in 
analytical tools capable of measuring E3 ligase activity.  Current techniques for investigating 
UPS activity often require large populations of cells or genetic modifications, restrictions which 
often exclude the potential for measuring samples obtained directly from a patient.   
Peptide reporters offer a means to overcome these shortcomings, especially when paired with 
chemical cytometry techniques such as CE-LIF.  In addition, peptide reporters boast several 
distinct advantages over current state of the art technologies.  Peptide reporters act as substrates 
for E3 ligases and thus directly measure enzymatic activity, which allows them to account for 
upstream effects in the UPS.  They are rapidly synthesized using SPPS, allowing rapid 
prototyping and refinement, as demonstrated by the construction of this library.  While not 
explored in this work, they are also capable of being loaded into cells in a variety of ways, 
including: pinocytosis, incorporation of a TAT sequence, or the addition of a myristoyl tag.39 
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These reporters were initially developed in HeLa S100 lysates, which provided a 
reproducible source of E1, E2, and E3 enzymes.  To quantify the kinetic parameters of the 
reporters, lysates were enriched with either wild-type or methylated ubiquitin.  To further 
validate the reporters, additional pull down experiments were performed allowing for analysis of 
only analytes with an ubiquitin moiety.  The kinetic parameters of the initial reporters were 
derived from time course assays, from which the best performers were selected for optimization.  
While kinetic studies have been done for some E3 ligases and specific degrons, there have been 
few comprehensive studies that examine multiple degrons under the same conditions.40-43 This 
work directly compared degron performances from several sources in both cytosolic lysates and 
freshly prepared lysates.  While the rates calculated for degrons with available data were lower 
than their predicated literature values, these values were obtained from artificial conditions, such 
as optimized in vitro recombinant protein assays or from using concentrated nuclear lysates.41, 44 
 One important characteristic of peptide reporters is their specificity, as there are several 
reports of promiscuity in kinase reporters throughout the literature; however, none have explored 
E3 ligases.45-47  Studies using p53 suggested that Hdm2 is no longer required for ubiquitination, 
and that the p53 reporters may have significantly reduced specificity.  This may prove to be an 
advantageous quality, as it could facilitate the development of a more global UPS reporter. 
 In conclusion, the body of work described in this chapter details the initial development 
of a peptide-based E3 ligase reporter that should be compatible with CE-LIF.  The work 
identified four key degrons that were optimized and further refined to enable optomized kinetic 
analysis of ubiquitination rates. 
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2.5 Figures and Tables 
1.1  
Figure 2.1 General design of library peptide reporters. Reporters consist of three key 
elements: (1) an E3 binding recognition site (i.e., degron), (2) a proximal lysine residue for 
ubiquitin conjugation, and (3) a fluorescent tag for detection and quantification.  Additionally, 
(4) an optional spacer element was included to standardize reporter length.   
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Figure 2.2 Preliminary validation of degron-based substrates.  Four example results of in 
vitro ubiquitination assays supplemented with either wild-type or methylated ubiquitin (MeUb).  
As expected, the degree of ubiquitination increases for (A) β-Catenin, (B) Bonger, (C) p53, and 
(D) IFNAR1 peptide reporters over time, and at different rates, demonstrating the importance of 
the degron element.  Unreacted peptide was run in the left-most lane to standardize results and to 
identify unreacted peptide, as indicated by the arrows.    
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Figure 2.3 Ubiquitination assay pull down results.  The results of ubiquitin pull down assays 
using wild type ubiquitin.  The four best performing reporters are shown, which incorporated 
degrons from: (A) β-Catenin, (B) Bonger, (C) p53, and (D) iNOS.  Assays were carried out in 
triplicate and used to calculate the kinetic parameters in Table 2.  
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Figure 2.4 Pulldown results of the expanded libraries.  The expanded peptide library for (A) 
Bonger, (B) iNOS, (C) p53, and (D) β-Catenin.  In vitro ubiquitination assays supplemented with 
ubiquitin were carried out followed by an ubiquitin pulldown.  Each expanded library was used 
to identify the optimal reporter length and lysine position.  All samples were incubated in the in 
vitro ubiquitination assay for 2 hours. 
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Figure 2.5 Poly-ubiquitination of optimized reporters.  Optimized reporters for Bonger (A, 
lane 1), iNOS (A, lane 2), p53 (A, lane 3), and β-Catenine (B, lane 1) were subjected to an in 
vitro ubiqutination assay supplimented with wild-type ubiqutin for 2 hours, followed by a 
ubiquitin pull down.  Poly-ubiqutination was observed in all cases, to varying degrees. 
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Figure 2.6 Optimized reporters ubiquitinated in cell lysates.  (A) Top performing peptides 
were incubated for 2 hours in lysates from four different cell lines (HeLa, U937, THP-1, and 
HL60), supplemented with wild-type ubiquitin, then subjected to a ubiquitin pulldown.  (B) A 
cell-free in vitro ubiquitination assay was carried out using the optimized p53-based reporter.  
Lane 1 contains all assay components. Lanes 2–4 are control experiments with key enzymatic 
components removed. The assay was probed using two commercial Mdm2 inhibitors: HLI-373 
(1,10 mM, lane 5–6 respectively) and NSC-66811 (1,10 mM, lanes 7–8, respectively). All 
reactions were incubated for 2 hours at 30 °C prior to halting the reaction with sample buffer. 
Arrow indicates unmodified substrate. 
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Figure 2.7 Kinetic analysis of reporter ubiquitination.  (A) Proposed model for multi-mono-
ubiquitination of the degron-based substrates. Rate constants correspond to Equations S1–S6 
representing substrate ubiquitination and peptidase dependent degradation (see reference 25). 
Computational fits (lines) for the three degron based substrates: Bonger (B), p53 (C), and iNOS 
(D), based on experimental observations (symbols). 
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Table 2.1 Reporter library and degron origins. Reporters were named according to either the 
protein from which they derived, or the researcher who first described them. Underlined regions 
indicate the minimal degron (if known).  Bold amino acids represented phosphorylated residues. 
The N-terminus of all peptides were acetylated and the C-terminus of all peptides were amidated. 
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Table 2.2 Reporter rate constants determined by kinetic analysis. Rates k1-k4 represent 
ubiqutination, while k5-k9 represent peptidase-dependent degradation as determined by a 
computational model (see Figure 2.7 and reference 25).    
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Chapter 3: Exploration of Expanded p53 Degron Library 
3.1 Introduction 
The ubiquitin proteasome system (UPS) is the primary enzymatic pathway for the 
degradation of misfolded or damaged proteins in cells.1, 2  At the heart of this process is the 
conjugation of the small protein ubiquitin to proteins, a process known as ubiquitination, which 
targets proteins to the proteasome for degradation.  Ubiquitination is a tightly regulated process 
that principally involves a cascade of three enzymes (in order of increasing levels of specificity): 
E1 activating, E2 conjugating, and E3 ligases.3  E3 ligases are the final arbitrators of the 
ubiquitination process that recognize the specific degradation signals, or degrons, on target 
proteins and facilitate their ubiquitination.  The importance of E3 ligases is highlighted in their 
abundance and diversity, with hundreds of known E3 ligases in  humans.1, 4   
Once E3 ligases recognize a degron on a target protein, they transfer activated ubiquitin to a 
proximal lysine residue on the protein, forming an isopeptide bond between the ubiquitin C-
terminal carboxylate and the lysine ε-amino group.  This process can be repeated such that 
additional ubiquitin proteins form a poly-ubiquitin chain off of a single lysine residue.  The 
ultimate fate of the protein depends on which of the ubiquitin molecule’s several lysine residues 
the chain originates. For example, chains formed on the 48th lysine residue are targeted to the 
proteasome for degradation, while chains formed on the 63rd lysine play a role in signal 
transduction for DNA repair.4  Acting in direct opposition to E3 ligases are deubiquitinating 
enzymes (DUBs), which selectively cleave the isopeptide bond between a protein and ubiquitin 
and thereby rescues the protein and allows ubiquitin to be reused in future ubiquitination events. 
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Because the UPS plays a key role in precisely controlling cellular protein levels, a vital 
cellular function, it has become a topic of intense interest as a target for molecularly targeted 
therapeutics.  Proteasome inhibitors such as Bortezomib and Carfilzomib revolutionized the 
treatment of multiple myeloma and kicked off a rush to develop new inhibitors for different 
components of the UPS, including E3 ligases, DUBs, and the proteasome.2, 5  However, with the 
push to develop these new therapeutics comes the need to develop tools capable of precisely 
quantifying the activity of UPS components.  The current gold standards, such as Western blots 
or ELISA (enzyme-linked immunosorbent assay), require relatively large sample sizes and can 
only analyze bulk cell lysate samples.  This makes discovery of subpopulations of cells 
impossible, as they only report a bulk population average.6 
Chemical cytometry is capable of overcoming these limitations; coupling fluorescently 
labeled peptide reporters with capillary electrophoresis (CE-LIF) has enabled precise 
quantification of enzymatic activity in samples as small as single cells.7  Peptide reporters have 
been used in previous work to investigate kinase, phosphatase, and peptidase activity in single 
cancer cells.8-10  Additionally, peptide reporters boast several distinct advantages: they can be 
rapidly synthesized and prototyped, do not require genetic engineering techniques, and are 
compatible with patient samples.  One of the most significant drawbacks to peptide reporters is 
their susceptibility to peptidases in cells, which rapidly degrade reporters, limit reporter lifetime, 
and convolute kinetic analyses. We have developed a strategy to overcome this drawback using a 
β-hairpin ‘protectide’ to produce a new generation of robust reporters that are resistant to 
peptidases.11, 12  In order to develop these next generation peptide reporters for E3 ligase activity, 
compact degron components must be identified and incorporated into the reporter design.  
Studies investigating several degron signals have demonstrated that their integration into native 
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proteins results in dramatically increased proteasome mediated degradation.13, 14  Though several 
degron sequences have been reported in the literature, the ability of the sequences to function 
once incorporated into peptide reporters appears to greatly depend on peptide length or 
posttranslational modifications such as phosphorylation.6, 15  The development of future E3 ligase 
peptide reporters would benefit greatly from a library of compact, potent degrons. 
The goal of this work was to build on previously reported work; specifically, to identify a 
shortened degron sequence taken from the tumor suppressor protein, p53.  Work done by Gu et. 
al. had previously established a 26 amino acid degron element that was key to E3 ligase MDM2 
(mouse double minute 2 homolog) recognition of p53.16  Follow-up work used this sequence as a 
starting point to develop an E3 ligase peptide reporter that incorporated the p53 degron.17  
However, the long peptide length proved to be problematic, as the reporter was rapidly degraded 
by peptidases in cell lysates.  A small library was synthesized to investigate the preferred 
ubiquitination site of the 26-amino acid sequence and made rough attempts to further shorten the 
original sequence while preserving the rates at which the reporter was ubiquitinated.  These early 
attempts suggested that the original reporter degron could be further refined, potentially 
producing a compact degron with improved kinetics.   This p53 degron therefore was an 
excellent candidate to be paired with a protectide; however, a shortened sequence first needed to 
be identified in order to facilitate the protectide strategy.  In this work, a library of nine reporters 
was synthesized and evaluated in an in vitro reaction using recombinant enzymes, then evaluated 
using SDS-PAGE.  More precise quantification was performed using reverse phase high 
performance liquid chromatography (HPLC) in order to calculate reporter ubiquitination 
kinetics.  Finally, a compact 5 amino acid degron component was tested against a panel of 
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inhibitors to investigate the HDM2 (human double minute 2 homolog) ligase specificity of the 
reporter.    
3.2 Experimental Design 
3.2.1 Synthesis of p53 library  
All peptides were synthesized using SPPS manually or using an automated peptide 
synthesizer (Creosalus TetrasUI Peptide Synthesizer, Louisville, KY).  Synthesis was carried out 
by Dr. Adam Melvin, Gregery Woss, or Lukas Dumberger, with Lukas carrying out the majority 
of the synthesis.  Synthesis was done on CLEARamide resin (Peptides Internationals) using 
Fmoc-[N]-protected amino acids (Advanced Chem, Louisville, KY).  Removal of Fmoc was 
done by gentle agitation in a solution of 2% DBU (1,8-diazobicyclie[5.4.0]undec-7-ene) and 2% 
piperidine suspended in DMF (dimethylformamide)  for 15 min twice.  Amino acids were 
activated using 4 equivalents of HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate) and 4 equivalents of HOBt (hydroxybenzotriazole) in DMF and NMP (N-
methylpyrrolidone) in the presence of 5 equivalents of DIPEA (N,N-diisopropylethylamine).  
For all natural amino acids, the coupling reaction was carried out twice for 30 minutes to 1 hour.  
In the case of Fmoc-Lys(ivDde)-OH, a single reaction was carried out using standard coupling 
agents over four hours to reduce reagent cost.  Following synthesis of the peptide, the N-
terminus was acetylated using 5% acetic anhydride and 6% 2,6-lutidine in DMF for 35 minutes. 
In order to conjugate a fluorescent tag to the peptide, ivDde was removed by gentle agitation 
in a solution of 3% hydrazine monohydrate in DMF for three minutes three times; removal of the 
ivDde protecting group was confirmed using the Kaiser test. Next, the peptide was gently 
agitated overnight in the dark while in the presence of 4 equivalents of 6-carboxyfluorescien 
(Chem Impex, Wood Dale, IL), 4 of equivalents HOBt, 4 equivalents of PyBOP (benzotriazol-1-
yl-oxytripyrrolidinophosphonium hexafluorophosphate), and 8 equivalents of DIPEA in DMF.  
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The peptide was then cleaved from the resin using TFA (trifluoroacetic acid), TIPS 
(triisopropylsilane), and H2O in a ratio of 95:2.5:2.5 for 3.5 hours, after which remaining TFA 
was evaporated under nitrogen.  The peptide products were then precipitated into ice cold ether, 
extracted into water, then lyophilized. 
Peptides were purified twice using reversed phase HPLC (Atlantis C-18 semi-preparative 
column), first using a 60-minute gradient of 95%/5% acetonitrile/water + 0.1% TFA to 5%/95% 
acetonitrile/water + 0.1% TFA, and then again using a 100-minute gradient.  Purification was 
carried out either by Dr. Adam Melvin, Gregery Woss, or Lukas Dumberger, with Lukas 
performing the majority of the purification. The peptide’s molecular weight was validated using 
ESI or MALDI mass spectrometry.  Peptides were then suspended in 50 mM phosphate buffer 
(pH 8.0) and quantified using a Nanodrop 2000 spectrophotometer. 
3.2.2 Tissue Culture 
HeLa S100 lysates were generated to provide components of the UPS that could be used 
reproducibly and consistently throughout the development process.  HeLa S100s were generated 
by Dr. Adam Melvin and Gregery Woss.  HeLa S3 cells (ATCC, Manassas, VA) were grown in 
Dulbecco’s modified eagle medium (DMEM) with 10% v/v bovine calf serum (HyClone, GE 
Healthcare Logan UT) and maintained in a 37 °C, 5% CO2 environment.  Cells were initially 
grown in T-75 culture flasks until 70% confluent.  Cells were then rinsed with phosphate-
buffered saline (PBS) and treated with 2 mL trypsin-EDTA for five minutes or until detached, at 
which point they were then spun down at 800-1200g for 10 min, resuspended in fresh media, and 
expanded into additional flasks.  Once 8 flasks had reached 70% confluence, cells were treated 
with trypsin-EDTA as described above and re-suspended in suspension growth media (RPMI 
1640 supplemented with 5% v/v bovine calf serum) to a density of 2 x 105 cells/mL in a 250 mL 
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spinner flask.  Cells were then allowed to grow with fresh media added to prevent exceeding a 
cell density of 5 x 105 cells/mL.  After 2-3 days of growth, cells were spun down at 800-1200g 
for 10 min and resuspended in fresh media in a 1 L spinner flask.  This process was repeated 
until the suspension volume reached 1 L, at which point the above process was repeated, the cells 
were transferred to a 3 L spinner flask to grow with fresh media added until the suspension 
reached a volume of 3 L and a density of 4-6 x 105 cells/mL, and the cells were harvested.  Cells 
were spun out of solution as described above, then washed with ice cold PBS and pelleted at 
1200g for 10 minutes.  The cell pellet volume was recorded as packed cell volume (PCV). 
5xPCV hypotonic buffer (10 mM HEPES pH 8.0, 10 mM KCl, 1.5 mM MgCl2, and 1 mM DTT) 
was then used to swell the cells over the course of 10 minutes at 4 °C, at which point cells were 
centrifuged at 18006g for 10 min.  This pellet was then resuspended in 2xPCV in hypotonic 
buffer and then lysed with approximately 10 strokes in a Dounce glass homogenizer.  The 
resulting lysed cells were then centrifuged for 10 min at 1200g. 
Following centrifugation, the resultant supernatant was collected as and supplemented with 
0.11xPCV of buffer B (0.3 M HEPES pH 8.0, 1.4 M KCl, and 30 mM MgCl2).  This solution 
was then centrifuged at 100,0006g for 60 minutes at 4 °C. The resulting supernatant was then 
collected and dialyzed twice, first overnight and again for 4 hours, in buffer D (20 mM HEPES 
pH 8.0, 100 mM KCl, 0.2 mM EDTA, 0.5 mM PMSF, 1 mM DTT, and 20% v/v glycerol) at 4 
°C. The lysate was then centrifuged one final time at 33,0006g for 20 min at 4 °C.  The resulting 
cytosolic lysates were then quantified using a Nanodrop 2000 (Thermo Scientific), aliquoted, and 
stored at -80 °C. 
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3.2.3 In vitro p53 ubiquitination assay using recombinant enzymes 
Evaluation of p53 ubiquitination was done using an in vitro ubiquitination assay using 
recombinant human enzymes.  This reaction was initially adapted from cell lysate-based 
ubiquitination reactions by Dr, Adam Melvin based on recommendations by the company Boston 
Biochem.  The reaction was then optimized by Gregery Woss.  The reactions were carried out by 
Lukas Dumberger and Gregery Woss, with Lukas carrying out the majority of them.  The 
reaction buffer was composed of 10 mM Tris-HCl (pH 7.6), 2 mM MgCl2, 2 mM DTT, 300 μM 
ubiquitin (Boston Biochem, Cambridge, MA), 1X ATP-Energy Regenerating Solution (ERS) 
(Boston Biochem, Cambridge, MA), 1 μM Ube1 (E1, Boston Biochem, Cambridge, MA), 10 μM 
UbcH5b (E2, Boston Biochem, Cambridge, MA), and 1 μM HDM2 (E3, Boston Biochem, 
Cambridge, MA).  In order to determine kinetic parameters, a range of peptide reporter 
concentrations was used (1 μM, 5 μM, 10 μM, 20 μM, and 30 μM).  Reactions were carried out 
at 30 °C for 2 h and halted either by freezing the sample prior to analysis via HPLC or by the 
addition of 40 μL Tricine Sample Buffer (BioRad, Hercules, CA) and heating at 90 °C for 5 min. 
For analysis by gel electrophoresis, samples were loaded into precast 16.5% Mini-PROTEAN 
Tris Tricine SDS-PAGE gels (Bio-Rad, Hercules, CA). Gels were visualized with a Typhoon 
Imager (GE Healthcare Life Sciences, Pittsburgh, PA). Quantification of gels was done using 
ImageJ software (US National Institute of Health).  Kinetic analysis was performed by 
comparing sample band intensity to unreacted parent peptide band intensity. 
3.2.4 HPLC analysis 
Analysis of reporter ubiquitination was carried out using an Agilent 100 HPLC system 
with a fluorescence detector and a Phenomenex Jupiter 300 C-18 column.  Following 
optimization of separation conditions by Gregery Woss, Lukas Dumberger carried out the large 
majority of HPLC runs.  Samples prepared in the reaction outlined above were stored at -20°C 
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until immediately prior to analysis, at which point they were quickly thawed to room 
temperature, spiked with an internal standard (10 μM fluorescein), and injected into the column.  
Separations occurred under a 15-minutemin gradient of 99.9% acetonitrile + 0.1% TFA to 99.9% 
water + 0.1% TFA.  As an internal control, unreacted parent peptide was analyzed prior to each 
round of analysis to ensure consistent column performance and validate peak migration times.  
Experiments were carried out in triplicate at all concentrations with the exception of the negative 
control peptide, which was only analyzed in triplicate at the 10 μM in order to conserve reagents.   
3.2.5 Inhibitor panel of p53 library 
Peptides were evaluated for ubiquitination activity in HeLa S100 lysates.  Reactions 
using cell lysates were carried out by Gregery Woss.  A 100 μL reaction buffer was prepared 
containing 10 mM Tris-HCl pH. 7.6, 5 mM MgCl2, 2 mM DTT, 20 μg per mL ubiquitin 
aldehyde (Boston Biochem, Cambridge, MA), 400 μg per mL ubiquitin (Boston Biochem, 
Cambridge, MA), 1X ATP ERS, 100 μM MG-132 (EMD Chemicals, Billerica, Massachusetts), 1 
μL PhosSTOP (Roche, Basel, Switzerland), 1 μL cOmplete ULTRA (Roche, Basel, Switzerland) 
and HeLa S100 cytosolic lysates diluted to a concentration of 2 mg/mL.  For experiments 
utilizing inhibitors, the reaction buffers were allowed to pre-incubate for 60 min following the 
addition of inhibitor but prior to the addition of the peptide reporter.  The inhibitor compounds 
were all obtained from LifeSensors (Malvern, PA), and were suspended in fixed volume of 
DMSO.  Inhibitors were used at 3x their listed IC50 value, with the following concentrations: 30 
μM serdementan, 0.27 μM nutlin-3, 150 μM SKPin C1, 300 μM SMER3, 90 μM thalidomide, 30 
μM PYR-41, or a DMSO vehicle control. Following addition of 10 μM peptide, samples were 
incubated for 2 hours at 37 °C. 
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To validate and pre-concentrate products containing an ubiquitin moiety, we utilized agarose 
beads coated with antibodies specific for ubiquitin (Agarose TUBES1, LifeSensors, Malvern, 
PA).  Once the ubiquitination reaction had been allowed for the desired time, it was halted by 
diluting with 280 μL TBS-T buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, and 0.1% v/v 
Tween-20).  20 μL Control-Agarose beads (LifeSensors, Malvern, PA) were then added to the 
sample to control for non-specific binding and the sample was placed on a tube rotator and 
agitated for 1 hour at 4 °C. Control beads were then pelleted by centrifuging the sample at 1800g 
for 5 minutes. The supernatant was collected and added to a fresh centrifuge tube containing 100 
μL of the Agarose-TUBES1 in TBS-T buffer.  Samples were kept on a tube rotator over night at 
4 °C then spun down at 1800g for 5 minutes.  The supernatant was then removed and the beads 
washed in 1 mL ice cold TBS-T five times, re-centrifuging at 1800g for 5 minutesmin.  
Following the final centrifugation, the beads were suspended in 50 μL of tricine sample buffer 
and heated for 5 minutesmin at 90 °C.  Samples were then stored at -20 °C until being loaded 
into gel for analysis. 
 
3.2.6 Data Analysis 
Data was analyzed by Dr. Adam Melvin, Gregery Woss, and Lukas Dumberger, with 
Lukas performing analyses for the majority of HPLC runs.  Pseudo-Michaelis-Menten kinetics 
analysis was spearheaded by Dr. Adam Melvin.  Data was analyzed using Origin 7.0 (OriginLab) 
to calculate the following parameters: the area of the ubiquitinated product peak, 𝐴𝑢𝑏; the area of 
the unreacted peptide, 𝐴𝑝; the width of each peak (𝑊1
2,
𝑝
,𝑊1
2
𝑢𝑏
); and the migration time of each 
peak (𝑡𝑝, 𝑡𝑢𝑏).  The additional parameter, column length, (𝐿) was obtained directly form the 
column used.  These variables were used to calculate the following parameters: The fraction of 
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the peptide ubiquitinated (𝑓𝑢𝑏), average peak width (𝑊1
2,
𝐴𝑣𝑔
), resolution (R), theoretical plates 
(N) and theoretical plate height (H).  The equations used to calculate these metrics are as 
follows: 
𝑓𝑢𝑏 = (
𝐴𝑢𝑏
𝐴𝑢𝑏 + 𝐴𝑝
) 
𝑊1
2,𝐴𝑣𝑔
=
𝑊1
2,𝑝
+𝑊1
2𝑢𝑏
2
 
𝑅 =
0.589(𝑡𝑝 − 𝑡𝑢𝑏)
𝑊1
2𝐴𝑣𝑔
 
𝑁 =
5.55𝑡2
𝑊1
2𝐴𝑣𝑔
2
 
𝐻 =
𝐿
𝑁
 
3.3 Results and Discussion 
3.3.1 Refinement of the p53 Degron Sequence 
Work done in the previous chapter detailed the original investigation of the 26 amino acid 
p53 degron identified by Gu et. al.16  A peptide reporter incorporating amino acids 92-112, an 
available lysine residue, and a fluorescent tag 
[KPLSSSVPSQKTYQGSYGFRLGK(FAM)KKK], were ubiquitinated in HeLa S100 cell 
lysates.15  The N-terminal lysine residue was not originally part of the degron sequence, but was 
previously incorporated into early studies and found to be a preferential ubiquitination site.  
Initial work also demonstrated that peptide reporters were capable of having multiple 
ubiquitination events occur at each lysine residue.  In order to simplify kinetic analysis, this 
reporter was redesigned to substitute the three C-terminal lysine residues with three arginine 
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residues.  Eight additional peptides were derived from this starting point (Figure 3.1A).  All 
peptides in this library were between 8-14 amino acids in length, each with a single 
ubiquitination site. It is important to note that the lysine residue near the peptide C-terminus is 
conjugated to fluorescein and thus is not available for ubiquitination.  Peptides 2, 4, 7 and 8 had 
N-terminal lysine residues, whereas peptides 3, 5, and 6 contained an internal lysine residue.  
The lysine residue of peptide 2 was replaced with a valine residue in the negative control peptide 
9, as valine is incapable of being ubiquitinated. 
 Peptides were assayed using recombinant human enzymes to allow for analysis in the 
absence of competing cellular reactions, such as degradation.  Peptides were incubated with 
Ube1 (an E1 activating enzyme), UbcH5b (an E2 conjugating enzyme) and HDM2 (an E3 ligase) 
along with ATP and buffering reagents to recapitulate cellular conditions.  Samples were 
separated using SDS-PAGE electrophoresis and analyzed using a fluorescent imager.  The 
presence of a fluorescent tag allowed for imaging without the need for antibodies, a major 
advantage of the reporter design.  Peptides 1-8 were all ubiquitinated, but to variable degrees, as 
seen in Figure 3.1B.  As expected, peptide 9 was not ubiquitinated, confirming that a lysine 
residue was required for reporter ubiquitination.  Quantifying ubiquitination bands revealed that 
peptides 2, 7, and 8 all performed well, exceeding the ubiquitination rate of peptide 1.  This is 
especially notable given that peptide 1 contained two potential ubiquitination sites, suggesting 
that peptide length plays a critical role in the ubiquitination kinetics of these reporters.  While 
peptides 7 and 8 appeared to be the most rapidly ubiquitinated, poor signal to noise ratio made 
precise quantification of these bands difficult. 
 Control experiments were carried out using peptide 1 to validate whether observed bands 
were due to ubiquitination of peptides (Figure 3.1C).  As expected, ATP, ubiquitin, Ube1, and 
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UbcH5b were are required for ubiquitination.  Omitting HDM2 did not prevent reporter 
ubiquitination, but did result in a depressed ubiquitination rate.  This result was not entirely 
unexpected; previous examples of similar behavior have been reported in the literature.  For 
example, UbcH5 has been observed to directly ubiquitinate Otub1, while other work suggested 
HMD2 primarily serves as a ‘landing pad’ for Ubch5b and p53.18, 19  Given the shortened nature 
of the peptides, and the abundance of UbcH5b-activated ubiquitin complexes, it is possible that a 
significant amount of reporter is directly interacting with the E2 enzyme, though ubiquitination is 
carried out more efficiently in the presence of HDM2.   
3.3.2 Separation of Peptide Reporter Ubiquitinated Reporter by HPLC 
A more precise analytical method than SDS-PAGE was necessary to precisely quantify the 
reporter ubiquitination rates.  Analytical HPLC has a well-established background as a means for 
measuring posttranslational modifications such as phosphorylation, deubiquitination, and 
ubiquitination.20-22  HPLC enables reproducible and precise quantification using relatively small 
sample sizes, and can accommodate controls, such as internal standards.  In order to evaluate the 
ubiquitination kinetics of the peptide reporter library, HPLC analysis methodology was 
developed.   
Peptide 7 was used to optimize the method of HPLC analysis based on its high performance 
in the initial trials.  Peptide 7 was subjected to the in vitro ubiquitination assay detailed in the 
previous section, then analyzed using a 15-minutemin gradient elution, which produced three 
distinct peaks (Figure 3.2A).  Parent peptide peak, labeled peak 2, was identified by spiking the 
reaction mix with unreacted peptide.  The identity of peak 3 was confirmed to be ubiquitinated 
peptide through a combination of mass spectrometry and experimental controls (Figure 3.2C).  In 
addition to these expected peaks, an unexpected peak appeared in all experiments (peak 1).  
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Control experiments and mass spectrometry were unable to identify the peak, but given its 
consistent area and appearance it is believed to be a contaminant in the ubiquitination assay 
mixture.  The peak area was relatively small compared to other peaks, so it was omitted for data 
analysis.  The separation of peptide and ubiquitinated peptide had a resolution of 3.37 ±0.33, 
with the parent peak having a theoretical plate number of 14157 ± 6360 and a theoretical plate 
height of 0.126 ± 0.13.  This separation laid the groundwork for the analysis of the peptide 
library by HPLC. 
3.3.3 Kinetic Analysis of the p53 Library by HPLC Quantification 
In order to determine the rate of ubiquitination for the peptide library, peptides were 
analyzed across a range of concentrations, from 1 μM up to 30 μM.  Separation of the parent 
peptide (peak 2) and ubiquitinated peptide (peak 3) was observed for all peptides at all 
concentrations (Figures 3.3A, 3.3C 3.3E, 3.4A, 3.4C, 3.4E, 3.5A, and 3.5C).  The area of the 
unreacted peptide (𝐴𝑝) and ubiquitinated reporter (𝐴𝑢𝑏) were used to calculate the fraction of 
ubiquitinated reporter, which was then used to calculate the ubiquitinated reporter concentration.  
This was used to calculate the rate of ubiquitinated peptide formation, which was plotted against 
the initial concentration of reporter (Figures 3.3B, 3.3D, 3.3F, 3.4B, 3.4D, 3.4F, 3.5B, and 3.5D).  
These plots demonstrated strong linear correlations, as demonstrated by their calculated 
correlation coefficients (R2) presented in Table 3.1.  This linear approximation between reaction 
velocity and substrate concentration suggested the reaction could be described using pseudo-
Michalis-Menten kinetics at very low substrate concentrations (Km >> C).  With this in mind, an 
aggregate vmax/Km was calculated to describe the reaction rates of the p53 peptide library (Table 
3.1). 
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 In line with the results of the SDS-PAGE analysis, peptide 7 appeared to have the most 
rapid ubiquitination kinetics (vmax/Km = 2.55 x 10-4 min-1).  The disparity between peptides 
highlights the impact that reporter length and lysine position play in ubiquitination kinetics.  
These results also suggest that the amino acid sequence GSYG (missing from peptides 3-6 and 
peptide 8) is important to ubiquitination.  While peptides 1 and 2 also contained this GSYG 
sequence, their relatively lower ubiquitination rate suggests that large sizes play a role in 
determining their ubiquitination rate.  These observations are also in line with earlier work done 
with the p53 peptide, in which a reporter containing the GSYG amino acid sequence performed 
better than p53 reporters lacking it.15  Taken together, this work suggests that peptide 7 is a 
potent compact degron that is ubiquitinated by UbcH5b and HDM2. 
3.3.4 Ubiquitination of the p53 Based Reporter in HeLa S100 Lysates 
The strong performance of peptide 7 suggested that it would be a good candidate for 
integration into a more robust peptide reporter.  However, it was it was key to validate the 
peptide’s performance in cell lysates prior to this step.  Though the recombinant ubiquitination 
assay was advantageous for reporter development and allowed us to minimize competing 
reactions, it was not clear that it provided an accurate recapitulation of the cellular environment.  
To investigate this, peptide 7 was evaluated in HeLa S100 cytosolic lysates.  This assay was 
similar to the recombinant enzyme assay with a key difference being the substitution of HeLa 
S100 lysates for the recombinant E1, E2, and E3 enzymes.  In order to verify ubiquitination and 
concentrate any ubiquitinated products, agarose beads coated with antibodies specific for 
ubiquitin (TUBES) were employed.  Additionally, we investigated the effect that six 
commercially available UPS inhibitors had on the ubiquitination of peptide 7 in HeLa S100 
lysates to see if the inhibitor of any enzyme class decreased ubiquitination rate.  The inhibitors, 
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nutlin-3, serdementan, SKPin C1, SMER3, and thalidomide were all E3 ligase inhibitors while 
PYR-41 was an E1 ligase (Figure 3.5).23-27  Lysates were treated with 3x the IC50 value of each 
inhibitor 60 minutesmin before peptide was added. 
As demonstrated by Figure 3.6, lane 1, peptide 7 was readily ubiquitinated in HeLa S100 
lysates, forming mono-ubiquitination bands as well as bands characteristic of di-, tri-, and tetra-
ubiquitination.  The E3 ligase inhibitors nutlin-3, serdementan, and thalidomide had no apparent 
effect on ubiquitination rate (Figure 3.6, lanes 2, 3, and 6).  SKPin C1, which inhibits the E3 
ligase SCF-Skp2, appeared to produce a slight decrease in poly-ubiquitination of the peptide but 
did not appear to effect mono-ubiquitination (Figure 3.5, lane 4).  SMER-3, which inhibits the 
E3 ligase SCF-MET30, had a more pronounced effect, apparently inhibiting both mono- and 
poly-ubiquitination (Figure 3.6, lane 5).  These results suggest that the shortened degron 
incorporated into peptide 7 might serve as a substrate for the SCF family of enzymes.  These 
enzymes consist of three large subunits: Skp1 (the bridging protein), cullin (the major structural 
scaffold), and RBX1 (the RING binding domain responsible of the binding of the activated E2-
ubiqutin complex).  The specificity of the SCF family of enzymes stems from the F-box contain 
proteins (such as Skp2 or β-TrCP), which recognize target proteins.  It is possible that peptide 7 
is recognized and ubiquitinated by the SCF complex;  the minimal degron sequence in peptide 7, 
GSYG, shares some similarities with degron sequences of proteins ubiquitinated by SCF E3 
ligases, including β-catenin (DSGIHSG), IFNAR1 (DSGNYS), and TAZ (HSREQSTDSG).15  
Interestingly, these sequences typically require a phosphorylate serine, unlike the GSYS degron. 
While the shortened substrate apparently loses its specificity for HDM2, it also gains a 
broader applicability, potentially acting as a more global indicator of ubiquitination rates.  This 
may be due to its very compact size, as the protein structure may play a large role in limiting 
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proteins interaction with E3 ligases.  These results also demonstrate that this minimal degron 
sequence was ubiquitinated in cell lysates, making it a good potential tool for next generation 
peptide reporter development. 
3.4 Conclusions 
This work sought to expand upon earlier work and isolate a compact degron sequence 
from a previously established p53-based E3 ligase peptide reporter that retained or enhanced its 
ubiquitination kinetics.  A library of nine peptides was synthesized and their ubiquitination 
kinetics in an in vitro ubiquitination assay were quantified.  The top performing peptide, 
KGSYGK(FAM)RRR, was then validated in cell lysates and demonstrated to be ubiquitinated.  
Experiments with inhibitors suggest that the new compact degron (GSYG) might act as a 
substrate for the SCF family of E3 ligases.  This shortened degron should be a useful tool in the 
development of future E3 ligase reporters, due to both its small size and broad applicability.  
When paired with new strategies, such as β-hairpins to increase peptide robustness and CE-LIF 
analysis, this work lays the ground work for the next generation of E3 ligase reporters.  
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3.5 Figures and Tables 
 
Figure 3.1 In vitro ubiquitination of peptide substrates based on a p53 degron. (A) Library 
of the nine peptides reporters evaluated in this study. Bold amino acid residues represent 
potential ubiquitination site lysines. FAM represents 6-carboxyfluorescein. (B) SDS-PAGE 
results demonstrating in vitro ubiquitination the peptide library.  Pictured are fluorescent bands 
corresponding to ~12 kDa, which is the expected weight of a mono-ubiquitinated peptide. (C) 
SDS-PAGE data showing control experiments using peptide 1 with the exclusion of a single 
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assay component (lanes 2–6) followed by SDS-PAGE.  Pictured are fluorescent bands 
corresponding to ~12 kDa, which is the expected weight of a mono-ubiquitinated peptide. 
 
Figure 3.2 HPLC separation of parent peptide from ubiquitinated peptide.  (A) 
Representative chromatogram showing the ubiquitination of peptide 7 (10 μM) and its separation 
using a C18-bonded silica analytical column.  The parent peptide is labeled as peak 2, and the 
ubiquitinated reporter is labeled peak 3. Peak 1 is believed to be a contaminant. (B) Mass 
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spectrometry data (MALDI-TOF) of peak 3. (C) Control experiments demonstrating the absence 
of peak 3 with the exclusion of peptide (i), E1 enzyme (ii), E2 enzyme (iii), or ubiquitin (iv).  
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Figure 3.3 Quantification of top performing reporter ubiquitination kinetics. Presented 
chromatograms showing the concentration-dependent ubiquitination of peptides 2 (A), 7 (C), and 
1 (E).  Peak 1 represents unidentified, non-reactive contaminant, peak 2 represents parent 
peptide, peak 3 represents ubiquitinated reporter, and peak 4 an internal standard (FAM, 6-
carboxyfluorescein).  Initial concentration of peptides 2 (B), 7 (D) and 1 (F) were plotted against 
the velocity of peptide ubiquitination μM s−1) (n = 3).  
72 
 
 
Figure 3.4 Quantification of reporter library ubiquitination kinetics (1/2).  Presented 
chromatograms showing the concentration dependent ubiquitination of peptides 3 (A), 4 (C), and 
5 (E). Peak 1 represents unidentified, non-reactive contaminant, peak 2 represents parent peptide, 
peak 3 represents ubiquitinated reporter, and peak 4 an internal standard (FAM, 6-
carboxyfluorescein).  Initial concentration of peptides 3 (B), 4 (D), and 5 (F) were plotted against 
the velocity of peptide ubiquitination (μM s−1) (n = 3). 
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Figure 3.5 Quantification of reporter library ubiquitination kinetics (2/2).  Presented 
chromatograms showing the concentration dependent ubiquitination of peptides 6 (A), and 8 (C). 
Peak 1 represents unidentified, non-reactive contaminant, peak 2 represents parent peptide, peak 
3 represents ubiquitinated reporter, and peak 4 an internal standard (FAM, 6-
carboxyfluorescein).  Initial concentration of peptides 6 (B), and 8 (D) were plotted against the 
velocity of peptide ubiquitination (μM s−1) (n = 3). 
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Figure 3.6 Ubiquitination of a p53-based peptide substrate in cell lysates. Peptide 7 (10 μM) 
was incubated in HeLa S100 cytosolic lysates for 2 h.  For inhibitor studies E1 and E3 enzyme 
inhibitors were added 1 h before the reaction. Each inhibitor was added with the following 
concentrations: nutlin-3 (0.27 μM), serdementan (30 μM), SKPin C1 (150 μM), SMER3 (300 
μM), thalidomide (90 μM), PYR-41 (30 μM), or a DMSO control. 
  
75 
 
Table 3.1 Ubiquitinated kinetic constants for p53-based peptide library.  Calculated kinetic 
parameters for each peptide along with their coefficient of determination (n=3). 
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Chapter 4: Characterization of OWRWR 
4.1 Introduction 
The controlled synthesis, post translational modification, and degradation of proteins are 
crucial to cell homeostasis, migration, and proliferation.1  The ubiquitin proteasome system 
(UPS) is a collection of enzymes that play a key role in this process, acting to modify proteins by 
conjugating them to the small protein, ubiquitin (i.e., ubiquitination).2 This post translational 
modification can evoke a litany of downstream effects, one of the most dramatic being the 
unfolding and degradation of ubiquitinated proteins.  Ubiquitination typically involves a cascade 
of increasingly specific enzymes, each beginning with the 76-amino acid-long ubiquitin protein.  
Adenosine triphosphate (ATP) drives ubiquitin activation via E1 activating enzymes, which form 
a thioester bond with ubiquitin. This complex is transferred to an E2 conjugating enzyme, which 
then interacts with an E3 ubiquitin ligase to further facilitate the transfer of ubiquitin to a 
targeted protein. A ubiquitination event completes once the E3 ligase conjugates the C-terminal 
carboxylate of ubiquitin to an ε-amino group of a proximal lysine, which can occur either 
directly or indirectly.3  
Following the initial ubiquitination event, additional ubiquitin proteins can conjugate to the 
original lysine-conjugated ubiquitin, creating a poly-ubiquitin chain.  The ultimate effect of 
ubiquitination depends on the length of these chains, as well as at which lysine residue the chains 
form. For example, chains formed from the 46th lysine residue are recognized by the regulatory 
elements of the enzyme ultimately responsible for protein degradation: the proteasome.  Recent 
work demonstrated that the ubiquitin chain length that is required for degradation depended 
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partially on the protein size, with a single ubiquitin being sufficient for proteins smaller than 150 
amino acids.4  Proteins smaller than 20-30 amino acids appear to not be degraded by the 
proteasome regardless of ubiquitin chain length, and may be too small for the proteasome to 
unfold and thread them into its catalytic core properly. The UPS system is stringently regulated 
in large part by E3 ligases, which recognize degradation signals (degrons) encoded within 
proteins. Being both plentiful and diverse, with >600 varieties known to exist in humans, E3 
ligases are capable of sensing degrons that range from simple amino acid sequences to complex 
signals that require additional post translation modifications.5 
Given the central role the UPS plays in cell homeostasis; it is unsurprising that it has become 
a focal point in drug discovery for the treatment of a broad span of diseases ranging from cancer 
to neurodegenerative diseases.6  The success of drugs targeting the proteasome, and the number 
of potentially targetable proteasome components have prompted hopes that UPS inhibitors may 
one day be comparable to kinase/phosphatase inhibitors.6, 7  The rapid increase in interest in the 
UPS has opened up a need to develop new and more powerful technologies to measure the 
activity of its components, in particular the E3 ligases.   
The two gold standards for measuring E3 ligase activity are Western blotting and ELISA 
(enzyme-linked immunosorbent assay); however, both come with significant drawbacks, such as 
being unable to identify sub-populations of cells, making them unsuited for analyzing patient 
samples.2, 8 Chemical cytometry overcomes these limitations, and can analyze individual cells.  
Notably, coupling the use of fluorescently labeled peptide reporters with capillary 
electrophoresis with laser induced fluorescence detection (CE-LIF) permits the monitoring of 
enzymes responsible for post translation modifications, such as kinases and phosphatases.9-11  
Peptide reporters themselves boast several advantages: they can be synthesized rapidly, 
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optimized through iterative processes, and do not require complex techniques such as genetic 
modifications in order to be incorporated into cells.12  Early work developing peptide reporters 
established a library of degrons that, when incorporated into a peptide reporter, resulted in 
ubiquitination in cell lysates.8  One substantial drawback to peptide reporters is that these 
substrates are rapidly degraded by intracellular peptidases.12  In the past, this degradation has 
been diminished through the incorporation of unnatural amino acids, but this process must be 
carefully tailored to individual reporters.12  In addition to unnatural amino acids, secondary 
structures have been shown to increase peptide lifetimes in the presence of intracellular 
peptidase.13  Working in close collaboration with the Waters lab, who provided their experience 
and expertise, Professors Allbritton and Waters hypothesized that by appending a well-folded β-
hairpin to the N-terminus, the unstructured degron element of our reporters would be protected, 
and the β-hairpin would thus serve as a ‘protectide’.14   
4.2 Experimental Design 
4.2.1 Peptide Synthesis 
All peptides were synthesized using solid phase peptide synthesis (SPPS) manually or using 
a TetrasUI automated peptide synthesizer (Creosalus, Louisville, KY).  Peptides were 
synthesized by Dr. Adam Melvin, Dr. Kaiulani Houston, Dr. Effrat Fayer or Gregery Woss.  
Peptides were formed on CLEARamide resin (Peptides International, Louisville, KY) beads.  
Synthesis was done using Fmoc-[N]-protected amino acids (Advanced Chem, Louisville, KY).  
Removal of Fmoc group was done mixing resin in in a solution of DMF (dimethylformamide) 
containing 2% DBU (1,8-diazobicyclie[5.4.0]undec-7-ene) and 2% piperidine over 15 minutes 
two times.  Amino groups were activated using 4 equivalents of HBTU (2-(1H-benzotriazol-1-
yl)-1,1,3,3-tetramethyluronium hexafluorophosphate), 4 equivalents of HOBt 
(hydroxybenzotriazole), and 5 equivalents of DIPEA (N,N-diisopropylethylamine) suspended in 
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DMF and NMP (N-methylpyrrolidone).  The coupling reaction was carried out twice for 30 
minutes to 1 hour for all natural amino acids.  Fmoc-Lys(ivDde)-OH was coupled in a single 
reaction using standard coupling agents over a 4-hour period in order to reduce reagent cost.  
Following the addition of all amino acids, the peptide’s N-terminus was acetylated through a 
reaction with 5% acetic anhydride and 6% 2,6-lutidine in DMF for 35 minutes. 
The ivDde protecting group was next removed with gentle mixing in a solution of 3% 
hydrazine monohydrate in DMF for three minutes three times, and was confirmed using the 
Kaiser test.  The peptide was fluorescently tagged by reacting overnight in 4 equivalents of 6-
carboxyfluorescien (Chemi Impex, Wood Dale, IL), 4 of equivalents HOBt, 4 equivalents of 
PyBOP (benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate), and 8 
equivalents of DIPEA in DMF.  The peptide was then cleaved from the resin using a mixture of 
TFA (trifluoroacetic acid), TIPS (triisopropylsilane), and H2O in a ratio of 95:2.5:2.5 over 3.5 
hours, after which the remaining TFA was evaporated under nitrogen.  50 mL of ice cold ether 
was then used to precipitate peptide products, which were then extracted into water.  These 
products were then frozen and the sample lyophilized. 
The peptides were next purified using reverse phase HPLC (Atlantis C-18 semi-preparative 
column).  Two solvent systems were used: solvent A (95% acetonitrile, 5% water, 0.1% TFA) 
and solvent B (5% acetonitrile, 95% water, 0.1% TFA).  Initially, the peptide was purified over a 
60-minute gradient from solvent A to solvent B, at which point product peaks were identified 
using ESI (electrospray ionization) or MALDI (matrix-assisted laser desorption/ionization) mass 
spectrometry.  Following initial purification, peptides were subjected to a second round of 
purification over a 100-minute gradient to minimize the possibility of closely migrating 
impurities.  Peptides were then lyophilized and re-suspended in 50 mM phosphate buffer (pH 
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8.0) or DMSO and quantified using a Nanodrop 2000 spectrophotometer (Thermo Scientific, 
Wilmington, DE). Peptides were stored at -20 °C until use; peptides suspended in DMSO were 
mixed with diluted 100 fold with 50 mM phosphate buffer (pH 8.0) prior to use.    
4.2.2 Cell culture and S100 Lysate generation 
Cell lysate experiments were carried out by Dr. Adam Melvin, Dr. Kaiulani Houston, or 
Gregery Woss.  OPM-2 cells (obtained Donald McDonnell, Duke University) were maintained in 
a 37 °C, 5% CO2 environment using RPMI 1640 media (Fisher, Hampton, NH) supplemented 
with 12% fetal bovine serum (HyClone, GE Healthcare Logan UT), 21.8 mM glucose, 8.6 mM 
HEPES (pH 7.4) and 1.0 mM sodium pyruvate. 
HeLa S3 cells (ATCC, Manassas, VA) were used to produce HeLa S100 lysates.  Cells were 
grown in Dulbecco’s modified eagle medium (DMEM) with 10% v/v bovine calf serum 
(HyClone) and maintained in a 37 °C, 5% CO2 environment.  Cells were grown in T-75 culture 
flasks until 70% confluent.  Cells were rinsed with PBS and treated with 2 mL trypsin-EDTA for 
five minutes at which point they were detached using gentle agitation and centrifuged at 800g for 
2 minutes, resuspended in fresh media and expanded into additional flasks.  Once 8 flasks had 
reached 70% confluence cells, cells were detached and re-suspended in a 250 mL spinner flask 
using suspension growth media (RPMI 1640 supplemented with 5% v/v bovine calf serum) with 
an initial density of 2 x 105 cells/mL.  Cells were allowed to grow with fresh media added 
periodically to prevent cells from exceeding a cell density of 5 x 105 cells/mL.  After 2-3 days of 
growth, cells were spun down at 800g for 10 minutes and resuspended in a 1 L spinner flask 
using fresh media.  Fresh media was added periodically to maintain a cell density between 2 x 
105 cells/mL to 5 x 105 cells/mL until the total volume reached 1 L.  The process was then 
repeated and cells were transferred to a 3 L spinner flask.  Cells were harvested once media 
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reached 3 L and cells researched a density of 4 x 105 cells/mL to 6 x 105 cells/mL.  Cells were 
centrifuged out of solution, then washed with ice cold PBS.  They were then pelleted at 1200g 
for 10 minutes.  The volume of this cell pellet was recorded as packed cell volume (PCV). Cells 
were suspended in 5 x PCV of hypotonic buffer (10 mM HEPES pH 8.0, 10 mM KCl, 1.5 mM 
MgCl2, and 1 mM DTT) and allowed to sit for 10 minutes at 4 °C, then centrifuged at 18006g for 
10 minutes.  This pellet was then resuspended in 2xPCV in hypotonic buffer and then lysed 
using approximately 10 strokes in a Dounce glass homogenizer.  The resulting lysate was 
centrifuged for 10 minutes at 1200g.  The resulting supernatant was collected as and 
supplemented with 0.11 x PCV using a buffer comprised of (0.3 M HEPES pH 8.0, 1.4 M KCl, 
and 30 mM MgCl2).  This mix was then centrifuged at 100,000g for 60 minutes at 4 °C. The 
supernatant was collected and then dialyzed at 4 °C in 1 L of 20 mM HEPES pH 8.0, 100 mM 
KCl, 0.2 mM EDTA, 0.5 mM PMSF, 1 mM DTT, and 20% v/v glycerol for 8 hours and then 
again for 4 hours. The concentrated lysate was then centrifuged a final time at 33,000g for 20 
minutes at 4 °C.  Lysates were then quantified using a Nanodrop 2000 (Thermo Scientific), 
aliquoted, and stored at -80 °C until use. 
4.2.3 Ubiquitin pull down assay 
Peptides were evaluated for ubiquitination activity in HeLa S100 lysates and validated using 
an antibody based pull down reaction.  Pull down reactions were carried out by Dr. Adam 
Melvin or Gregery Woss.  A 100 μL reaction buffer was prepared composed of 10 mM Tris-HCl 
pH. 7.6, 5 mM MgCl2, 2 mM DTT, 20 μg/mL ubiquitin aldehyde (Boston Biochem), 400 μg/mL 
ubiquitin or methylated ubiquitin (Boston Biochem, Cambridge, MA), 1X ATP ERS (Boston 
Biochem, Cambridge, MA), 100 μM MG-132 (EMD Chemicals, Billerica, Massachusetts), 1 μL 
PhosSTOP (Roche, Basel, Switzerland), 1 μL cOmplete ULTRA (Roche, Basel, Switzerland) 
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and HeLa S100 cytosolic lysates diluted to a concentration of 2 mg/mL.  For experiments 
utilizing inhibitors, the reaction buffers containing cell lysates were allowed to pre-incubate for 
60 minutes prior to addition of the peptide reporter.  The inhibitor compounds were all obtained 
from LifeSensors (Malvern, PA) and were suspended in fixed volume of DMSO.  Inhibitors were 
used at three times their listed IC50 value, with the following concentrations: 30 μM 
serdementan, 0.27 μM nutlin-3, 150 μM SKPin C1, 300 μM SMER3, 90 μM thalidomide, 30 μM 
PYR-41, or a DMSO vehicle control.  The reaction was started with the addition of 4.2 µg 
peptide reporter and incubated for 2 hours at 37 °C.  
In order to validate and pre-concentrate products containing an ubiquitin moiety, agarose 
beads coated with antibodies specific for ubiquitin (Agarose TUBES1, LifeSensors) were 
utilized.  Once the ubiquitination reaction had been allowed for the desired time it was halted by 
diluting with 280 μL TBS-T buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, and 0.1% v/v 
Tween-20).  20 μL Control-Agarose beads (LifeSensors, Malvern, PA) were then added to the 
sample to control for non-specific binding and the sample was placed on a tube rotator and 
agitated for 1 hour at 4 °C. Control beads were then pelleted by centrifuging the sample at 1800g 
for 5 minutes, and the supernatant was collected and added to a fresh centrifuge tube containing 
100 μL of the Agarose-TUBES1 in TBS-T buffer.  Samples were kept on a tube rotator over 
night at 4 °C then spun down at 1800g for 5 minutes.  The supernatant was then removed and the 
beads washed in 1 mL ice cold TBS-T five times, re-centrifuging at 1800g for 5 minutes.  
Following the final centrifugation, the beads were suspended in 50 μL of tricine sample buffer 
and heated for 5 minutes at 90 °C.  Samples were then stored at -20 °C until being loaded into 
gel for analysis. 
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Peptides were evaluated for ubiquitination activity in HeLa S100 lysates.  A 100 μL reaction 
buffer was prepared containing 10 mM Tris-HCl pH. 7.6, 5 mM MgCl2, 2 mM DTT, 20 μg per 
mL ubiquitin aldehyde (Boston Biochem), 400 μg per mL ubiquitin (Boston Biochem), 1X ATP 
ERS (Boston Biochem), 100 μM MG-132 (EMD Chemicals), 1 μL PhosSTOP (Roche), 1 μL 
ULTRA (Roche) and HeLa S100 cytosolic lysates diluted to a concentration of 2 mg/mL.  For 
experiments utilizing inhibitors, the reaction buffers were allowed to pre-incubated for 60 
minutes following the addition of inhibitor but prior to the addition of peptide reporter.  The 
inhibitor compounds were all obtained from LifeSensors and suspended in fixed volume of 
DMSO.  Inhibitors were used at three times their listed IC50 value, with the following 
concentrations: 30 μM serdementan, 0.27 μM nutlin-3, 150 μM SKPin C1, 300 μM SMER3, 90 
μM thalidomide, 30 μM PYR-41, or a DMSO vehicle control. Following addition of peptide, 
samples were incubated for 2 hours at 37 °C. 
Ubiquitinated reporter was isolated using a ubiquitin pull-down assay. Reporter was 
concentrated and the cell lysate debris removed to readily detect and quantify the reporter on 
SDS-PAGE gels with the aid of a fluorescein tag. The ubiquitin pull down assay was carried out 
at the indicated times at 37 °C in a total reaction volume of 100 µL containing assay buffer (10 
mM Tris-HCl pH 7.6 and 5 mM MgCl2) with 2 mM DTT, 20 µg/mL ubiquitin aldehyde (Boston 
Biochem), 100 μM MG-132 (EMD Chemicals), 400 μg/mL ubiquitin, methylated ubiquitin, or 
no Lys ubiquitin (Boston Biochem), 1X ATP energy regenerating solution (ATP-ERS, Boston 
Biochem), 4.2 µg of indicated peptide substrate, and 2 mg/mL HeLa S100 cytosolic lysates as 
the source of E1, E2, and E3 enzymes. At the end of the indicated times, samples were incubated 
with Control-Agarose beads (LifeSensors), diluted in TBS-T buffer (20 mM Tris-HCl pH 8.0, 
150 mM NaCl, and 0.1% v/v Tween-20), for 60 minutes on a tube rotator at 4 °C.  Samples were 
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subsequently centrifuged at 1800g for 5 minutes to pellet and remove control beads.  The 
supernatant was transferred to a solution of Agarose-TUBEs (LifeSensors, Malvern, PA) diluted 
in TBS-T and incubated overnight on a tube rotator at 4 °C.  Ubiquitin-bound beads were washed 
5X with 1X TBS-T and then the samples were eluted off of the bead with 2X tricine sample 
buffer, heated for 5 minutes (>90 °C), and then isolated by centrifugation for 5 minutes at 
13000g.  Samples were loaded onto SDS-PAGE gels (precast 16.5% Mini PROTEAN Tris-
Tricine, Bio-Rad) using 1X tris-tricine running buffer and visualized with a Typhoon Imager 
(GE Healthcare Life Sciences).  Gels were quantified using ImageJ (US National Institute of 
Health) by comparing sample intensity to unreacted parent peptide intensity, which is not 
depicted in the gels.   
Pull down assays performed in the presence of chemical inhibitors were completed as 
described above, except that the reaction mixture contained 10 μM peptide and was 
supplemented with 1 μL of cOmplete ULTRA and 1 μL of PhosSTOP. The HeLa S100 lysates 
were pre-incubated for 60 minutes with the following single inhibitor compounds (all obtained 
from LifeSensors) at the following concentrations prior to adding the remaining reaction mixture 
components (each are three times the listed IC50 value for each compound): 30 μM serdementan, 
0.27 μM nutlin-3, 150 μM SKPin C1, 300 μM SMER3, 90 μM thalidomide, or 30 μM PYR-41. 
The reaction mixture was incubated at 37 °C for 2 hours and then subjected to ubiquitin-
conjugated protein isolation as described above.  Inhibitor studies were initially started by Dr. 
Kaiulani Houston, then re-optimized and carried out by Gregery Woss.  Samples were separated 
using SDS-PAGE and visualized with a Typhoon imager. 
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4.2.4 Circular dichroism  
Peptide concentrations were determined based on absorbance of FAM at 492 nm.  CD 
spectroscopy data was collected by Dr. Kaiulani Houston using an Applied Photophysics 
Chiroscan Circular Dichroism Spectrophotometer. Spectra were generated at 25 °C with a 
wavelength scan (260-185 nm) using 0.5 s scanning in a 0.1 cm cell. All peptides were at a final 
concentration of 40 μM in 10mM sodium phosphate buffer (pH 8.02). 
4.2.5 Peptidase degradation reactions  
Initial degradation studies were done by Dr, Kaiulani Houston using commercially available 
peptidases with analysis by HPLC; however, following several setbacks, peptide degradation 
studies were carried out in lysates prepared from the OPM2 cell line by Gregery Woss.    Briefly, 
1 x 106 cells/mL OPM2 cells were harvested, washed twice in PBP (137 mM NaCl, 10 mM 
Na2HPO4, 27 mM KCl, and 1.75 mM KH2PO4 at pH 7.4) and pelleted at 800g.  The cell pellet 
was re-suspended in an approximately equivalent volume of mammalian protein extraction 
reagent (MPER, ThermoFisher, Wilmington, DE), then vortexed for 10 minutes at room 
temperature.  Following this, the mixture was centrifuged at 14,000g for 15 minutes at 4 °C and 
the supernatant transferred to a fresh centrifuge tube and stored on ice until use.  Total protein 
concentration was determined using fluorescamine as previously described12.  To investigate 
peptide stability, 10 μM peptide was incubated with lysates diluted to a total protein 
concentration of 2 mg/mL in an assay buffer (10 mM Tris-HCL, pH 7.6) at 37 °C in the dark. 
Aliquots of the reaction mixture were removed at set intervals, at which point further peptidase 
activity was quenched by heating the aliquots at 90 °C for 5 minutes followed by immediately 
freezing in liquid nitrogen and then storage at -20 °C until analysis by CE.  The 0 minute time 
point measurements were made using lysates that were heat killed prior to peptide incubation.  
Samples were analyzed using a Beckman Coulter ProteomeLab™ PA800 automated CE system 
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(Brea, CA) (CE-LIF, 488 nm) as previously described.12  Prior to CE analysis, samples were 
thawed to room temperature and diluted 1:100 in separation buffer (125 mM Sodium 
Tetraborate, 3% v/v Tween-20, pH 8.5).  The capillary was washed with 1 M NaOH for 2 
minutes, dH2O for 2 minutes, and separation buffer for 2 minutes.  Separation was carried out in 
a fused-silica capillary (30 μm inner capillary, 360 μm outer capillary, Polymicro Technologies, 
Pheonix, AZ) with a total length of 30 cm and an effective length of 20 cm.  Samples were 
injected into the capillary by applying 0.5 psi pressure for 5 seconds, and separation was initiated 
by applying a negative voltage of 6.5 kV. Percent intact peptide remaining was calculated by the 
corrected area under the parent peptide peak divided by the total corrected peak area (i.e., the 
area under all peaks of the electropherogram) for each time point. The identity of the parent 
peptide peak was confirmed using the parent peptide alone and verified with the t=0 minute 
electropherogram. The data was analyzed using commercial software (32 Karat, version 8.0, 
Beckman Coulter). All degradation reactions and analysis were performed in triplicate. 
4.3 Results and Discussion 
4.3.1 Ubiquitination of protectide based reporters 
Previous work demonstrated that peptide reporters could be ubiquitinated in cell lysates.2, 8, 15  
The basic structure of these reporters consisted of a short degron sequence, an available lysine 
reside to which ubiquitin could conjugate, and a fluorescent tag for detection and quantification.  
Early studies had demonstrated that an artificial degron developed by Bonger et. al. had rapid 
ubiquitination kinetics in cytosolic lysates.8, 16  Unfortunately, the peptide was also rapidly 
degraded by intracellular peptidases, mitigating its usefulness as an E3 ligase reporter.  It was 
hypothesized that a more robust reporter could be produced by incorporating a large, well-folded 
β-hairpin, or ‘protectide’, onto the N-terminus of the peptide.  Working in close collaboration 
with the Waters lab, and in particular Dr. Kaiulani Houston who did much of the initial work on 
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this project, Dr. Houston designed a protectide-degron conjugate, which was a modified version 
of a protectide that was previously characterized, OWOWO, which improved peptide stability in 
the presence of peptidases (Figure 4.1A).13, 14  A reporter consisting of an N-terminal OWOWO 
protectide and the compact Bonger degron (RRRG) joined by a PEG (polyethylene glycol) 
spacing element was synthesized using SPPS (OWOWO-RRRG, Figure 4.1A).  This peptide was 
then tested using an in vitro ubiquitination reaction with HeLa S100 cytosolic lysates 
supplemented with methylated ubiquitin (MeUb).  These analytes were confirmed as 
ubiquitinated products using agarose beads coated in ubiquitin-specific antibodies (TUBEs).  As 
expected, the peptide was ubiquitinated in a time-dependent manner (Figure 4.1B, lanes 1,2); 
surprisingly, the results also indicated multiple ubiquitination products despite using MeUb, 
which is incapable of forming poly-ubiquitin chains.  This result suggested that multiple mono-
ubiquitination events occurred, and because OWOWO-RRRG contained a single lysine residue, 
we suspected that the ornithine residues within the OWOWO protectide itself were being 
ubiquitinated. 
 To test this hypothesis, OWOWO was subjected to the same ubiquitination assay as 
OWOWOW-RRRG using both MeUb and wild-type ubiquitin (Figure 4.1B, lanes 3-6).  
Interestingly, OWOWO was ubiquitinated in a time-dependent fashion in both cases, suggesting 
not only were the ornithine residues capable of being ubiquitinated, but that OWRWR itself was 
acting as a degron.  Though initially unexpected, the ornithine ubiquitination is not entirely 
surprising given the similarity of lysine and ornithine structures.  The results of initial 
experiments with MeUb were indicative multi-mono-ubiquitination events, a phenomenon 
previously observed in peptides with multiple potential ubiquitination sites.  To further confirm 
this, control experiments with OWOWO were carried out using an assay supplemented with 
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mutated lysine (No K Ub) without lysine residues (K→R), as well as lysates not supplemented 
with ubiquitin at all, in order to confirm that bands were not the result of endogenous ubiquitin 
(Figure 4.2).  These results indicated that endogenous ubiquitin may play a small role in the 
formation of multi-ubiquitination bands even when the lysate is supplemented with MeUb or No 
K Ub. 
 In order to further characterize OWOWO as a degron, a sub-library of four new peptides 
was synthesized: OWRWR, RWOWR, RWROW, and RWRWR (Figure 4.1A).  The majority of 
the work comparing these four peptides was done by Dr. Adam Melvin and Dr. Kaiulani 
Houston.  The first three peptides were similar to OWOWO but with two of the ornithine 
residues replaced with arginine residues; arginine was selected because it possessed a positive 
charge but could not be ubiquitinated.  By eliminating all but a single potential ubiquitination site 
on the reporter, the preferential ubiquitination site could be determined.  RWRWR served as a 
negative control, with all ornithine residues (e.g., potential ubiquitination sites) replaced with 
arginine residues.  These peptides were each tested in HeLa S100 lysates supplemented with 
either wild-type ubiquitin or No K Ub (Figure 4.1C).  OWRWR exhibited the highest degree of 
ubiquitination, comparable to OWOWO.  RWOWR and RWRWO both exhibited ubiquitination, 
but to a smaller extent.  As expected, RWRWR exhibited no ubiquitination, further supporting 
that the ornithine residues in the OWOWO library were the sites of ubiquitin conjugation.  
4.3.2 Kinetic Analysis of β-hairpin Ubiquitination 
Initial studies using both OWOWO-RRRG and OWOWO indicated that the two peptides had 
comparable ubiquitination rates, suggesting that in addition to being highly degradation-resistant, 
OWOWO and OWRWR were potent degrons in their own right.  To compare OWOWO and 
OWRWR ubiquitination kinetics to those of other peptides, the kinetic parameters of each 
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peptide were determined.  Additionally, an unstructured variant of OWOWO (Scram-OWOW) 
was synthesized and evaluated to determine what role, if any, the β-hairpin structure played in 
the ubiquitination of these degrons.  Kinetic data was obtained using a time course assay in HeLa 
S100 lysates supplemented with No K Ub (Figure 4.3A, 3C, and 4A).  Multi-ubiquitination was 
observed with both peptides, likely the result of multi-mono-ubiquitination or poly-
ubiquitination by endogenous ubiquitin.  The intensity of each ubiquitination band was 
normalized to a standard of unreacted peptide and the fraction of the peptide ubiquitinated over 
time was calculated.  These values were used to generate kinetic parameters for each reporter, 
using a stepwise ubiquitination kinetics model developed by Dr. Adam Melvin, similar to the one 
presented in Chapter 2 of this document.8  This computational model used the observed 
ubiquitination rate to produce first order reaction kinetics based off of four kinetic rate constants: 
mono- (k1), di- (k2), tri- (k3) ubiquitinated species, and the loss of peptide via either degradation 
or de-ubiquitination (k4). (Figure 4.3B, 4.3D, 4.4B) 
 Interestingly, mono-ubiquitination was the dominant reaction product for both the 
OWOWO and OWRWR peptides (k1 = 2.5 and 3.5, k2 = 0.9 and 0.9, k3= 0.8 and 0.9 
respectively, Figure 4.3B, 4.3D) while Scram-OWOWO exhibited a higher degree of both di- 
and tri-ubiquitination (k1 = 2.8 and 3.5, k2 = 1.4, k3= 1.4, Figure 4.4B).  This is suspected to be 
due to a lack of secondary structure in the peptide, which likely increased the availability of the 
internal ornithine residues for multi-mono-ubiquitination.  The kinetic model achieved a good fit 
for all three peptides tested, with low values for the cSSD and Pearson correlation coefficient 
values near 1 for most of the species tested (Figure 4.3F and 4.4C).  
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4.3.3 Characterization of the β-hairpin Degron Structure  
Previously described and well-characterized β-hair peptides, WKWK and WRWR, served as 
the template for OWOWO and, subsequently, OWRWR.17, 18  WKWK and WRWR structures 
were well-folded according to NMR (nuclear magnetic resonance spectroscopy) and CD 
(circular dichroism) characterization (>93% in both cases); however, it was unknown what effect 
the modifications made to OWOWO and OWRWR would have on these well-folded structures.  
To investigate these effects, CD experiments were carried out using OWOWO, OWRWR, and an 
unstructured, scrambled version of OWOWOs sequence: Scram-OWOWO. 
These experiments were carried out by Dr. Kaiulani Houstan, but warrant discussion here.  
The CD spectrum of the OWOWO peptide displayed the expected characteristics for this class of 
β-hairpin peptides with a minimum near 205 nm (Figure 4.5). Additionally, a minimum near 215 
nm and maximum near 225 nm were observed that derived from the exciton coupling of the 
cross-strand Trp residues’ indole rings, providing further evidence of the correct fold and 
register.19 These spectra are consistent with the CD spectrum of the related peptide, WKWK, and 
while the mean residue ellipticities of OWOWO and OWRWR differ, neither exhibited the peak 
at 195 nm characteristic of a random coil structure.  Scram-OWOWO served as a negative 
control for these experiments, and differed significantly from OWOWO, with a minimum near 
195 nm that did suggest a random coil structure.  
4.3.4 Resistance of OWRWR to Intracellular Peptidases 
Work by Cline et al. had previously demonstrated that β-hairpins increased resistance to 
peptidase-mediated degradation in cytosolic environments relative to unstructured peptides.14  
CD experiments suggested that OWRWR had a similar structure to a β-hairpin, so it was 
strongly expected that OWRWR would increase peptidase resistance comparably.  To test this 
hypothesis, OWRWR, an unstructured version of OWRWR (Scram-OWRWR), and an 
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unstructured control peptide (III-67B) were subjected to freshly-prepared OPM2 lysates.  
Peptides were incubated at 37 °C at varying lengths of time, after which cellular reactions were 
halted by heating the sample at 90 °C for 5 minutes.  Peptides were then analyzed using CE, 
which allowed for separation of degraded peptide fragments from un-degraded peptide.   
OWRWR was highly robust in OPM2 lysates (Figure 4.6, squares), with 80% of the peptide 
intact after 180 minutes, corresponding to a half-life of 630 minutes.  Scram-OWRWR (Figure 
4.6, circles) quickly degraded with a half-life just 30 minutes.  Finally, an additional control 
peptide, III-67B (FAM-GGAYAATKKKA), which had been previously characterized was used 
as an additional control, was found to have a half-life of only 4 minutes in OPM2 lysates (Figure 
4.6, triangles).12  These results highlight the importance of the well-folded β-hairpin structure in 
conferring resistance to intracellular peptidases.   
4.3.5 Determination of OWRWR E3 Ligase Specificity 
Experiments using cytosolic lysates demonstrated that OWRWR was ubiquitinated by cells, 
but because it was not derived from a known degron, it was unclear what components of the UPS 
were responsible for its ubiquitination.  In order to investigate which classes of E3 ligases were 
potentially responsible for OWRWR ubiquitination, in vitro ubiquitination experiments were 
carried out in the presence of a panel of E3 ligase inhibitors as well as an E1 inhibitor.   
Cytosolic lysates were incubated for one hour with one of five E3 ligase inhibitors (serdemetan 
nutlin-3, SKPin C1, SMER3 [small molecule enhancer of rapamycin 3], and thalidomide), the E1 
enzyme inhibitor PYR-41, or a DMSO control (Figure 4.7)20-24. Each inhibitor was added at a 
concentration three times that of its established IC50 value.  The reaction buffer was also 
supplemented with wild-type ubiquitin, a DUB inhibitor (ubiquitin aldehyde) and a proteasome 
inhibitor (MG-132).  OWRWR was allowed to incubate in this mixture for 2 hours at 37 °C. 
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 The E3 ligase inhibitors nutlin-3, serdementan, and thalidomide (Figure 4.7, Lanes 2, 3, 
and 6, respectively) had quantifiable effect on the ubiquitination of the OWRWR peptide, 
suggesting that the enzymes they inhibit were not primarily responsible for OWRWR 
ubiquitination.  SMER3 significantly reduced both the poly- and mono-ubiquitination of 
OWRWR (Figure 4.7, Lane 5).  SKPin C1 (Figure 4.7, Lane 4) appeared to reduce poly-
ubiquitination, but not mono-ubiquitination.  SMER3 is a specific inhibitor of the E3 ligase SCF-
MET30, whereas SKPin C1 inhibits the cullin-RING ubiquitin E3 ligase SCF-Skp2.22, 23  Taken 
together, this suggests that OWRWR could act as a reporter for the SCF family of E3 ubiquitin 
ligases.  This family of E3 ligases contains three core subunits and a variable F-box protein (e.g., 
Skp2 or Met30).  This variable F-box protein enables these E3 family members to recognize and 
bind to specific target proteins. The results presented here suggest that the β-hairpin OWRWR 
was recognized and ubiquitinated by an SCF complex; however, it does not appear ubiquitination 
was constrained to a single F-box protein as a recognition metric. 
SCF E3 ligase inhibitors have been known to target specific proteins in cells, however it is 
possible that they recognize a wide range of small degrons, such as OWRWR.  Work in chapter 
3 of this document found that SKPin C1 and SMER3 also impaired ubiquitination in a nine 
amino acid-long peptide reporter based on a MDM2 binding region on the tumor suppressor p53 
(KGSYGK(FAM)RRR).15 Given these observations, it is possible that the SCF family of E3 
ligases may lack specificity when it comes to the ubiquitination of short peptide sequences, 
perhaps favoring polycationic peptides.  Interestingly, The E1 ubiquitin-activating enzyme 
inhibitor PYR-41 had no quantifiable effect on the ubiquitination of OWRWR (Figure 4.7, Lane 
7), suggesting that it may not target the E1 enzyme involved in OWRWR ubiquitination.   
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4.4 Conclusions 
In this work, we present work characterizing OWRWR, a 12-residue β-hairpin peptide that 
acts an E3 ligase reporter, and demonstrated substantial robustness in the presence of 
intracellular peptidases.  OWRWR was optimized from the protectide OWOWO, after it was 
determined that it functioned as a degron independently of an additional degron sequence.  
Following a screen of E3 ligase inhibitors, we found evidence to suggest that OWRWR is a 
potential substrate of the SCF family of E3 ligases, an important group of E3 ligases that has 
been linked to several diseases.25  This protectide-based primary degron is thus a promising new 
tool as a reporter for detecting ubiquitination and potentially characterizing proteasome activity.  
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4.5 Figures and Tables  
 
Figure 4.1 Ubiquitination of β-hairpin peptides in cell lysates.  (A) Names and sequences of 
peptides studied. Bold amino acids (O = ornithine) correspond to potential ubiquitination sites. 
Peptides are acetylated at the N-terminus and amidated at the C-terminus. FAM denotes 6-
carboxyfluorescein. (B) Ubiquitination of β-hairpin conjugated to a known degron (OWOWO-
RRRG, Lane 1-2) compared to β-hairpin alone (OWOWO, Lane 3-6) using either ubiquitin or 
methylated ubiquitin (MeUb). Ubiquitin-conjugated peptides were purified using a ubiquitin pull 
down, separated using SDS-PAGE, and visualized using the fluorescein tag. Relative protein 
sizes (kDa) are compared to values obtained from a fluorescent protein marker (left of the gel).  
(C) The optimal ubiquitination site, ornithine, was identified using ubiquitin or no lysine 
ubiquitin. All reactions were incubated at 37 °C for 2 hours. 
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Figure 4.2 Ubiquitination of OWOWO in cell lysates. OWOWO demonstrates both multi-
mono-ubiquitination and poly-ubiquitination.  Ubiquitin-conjugated peptides were purified using 
a ubiquitin pull down, separated using SDS-PAGE, and visualized using the fluorescein tag. 
Relative protein sizes (kDa) are compared to values obtained from a fluorescent protein marker 
(left).     
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Figure 4.3 Time-dependent ubiquitination of OWRWR (A) and OWOWO (C) peptides. 
Experimental data points for mono-(closed squares), di-(closed circles), and tri-(open circles) 
ubiquitinated species for OWRWR (B) and OWOWO (D). The Y axis depicts the relative 
ubiquitination (Ci/Co). The lines indicate the best fit of the data to the kinetic model. (E) Summary 
of the kinetic rate constants as determined by the kinetic model. The rate constants correspond to 
mono- (k1), di-(k2), or tri-(k3) ubiquitinated species along with a term (k4) for peptide unable to 
participate in the reaction. cSSD is the cumulative sum of the squared difference minimized in the 
model to achieve the desired fit. Pearson correlation coefficients (rxy) describe goodness-of-fit 
between the model and experimental data for mono-, di-, and tri-ubiquitinated species. 
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Figure 4.4 Time-dependent ubiquitination of Scram-OWOWO (A).  (B) Experimental data 
points for mono-(closed squares), di-(closed circles), and tri-(open circles) ubiquitinated species. 
The Y axis depicts the relative ubiquitination (Ci/Co). The lines indicate the best fit of the data to 
the kinetic model. (C) Summary of kinetic rate constants as determined by the kinetic model. The 
rate constants correspond to mono- (k1), di-(k2), or tri-(k3) ubiquitinated species along with a term 
(k4) for peptide unable to participate in the reaction. cSSD is the cumulative sum of the squared 
difference minimized in the model to achieve the desired fit. Pearson correlation coefficients (rxy) 
describe goodness-of-fit between the model and experimental data for mono-, di-, and tri-
ubiquitinated species.  
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Figure 4.5 Circular dichroism spectra of a β-hairpin degron. Experiments were performed 
using 40 µM peptide in 10 mM sodium phosphate buffer, pH 8 at 25 °C. Scram-OWOWO (blue) 
was determined to be a random coil structure while OWOWO (green) and OWRWR (red) peptides 
exhibited spectra associated with a well-folded, β-sheet conformation. 
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Figure 4.65 Capillary electrophoresis analysis of peptide degradation in OPM2 lysates. 
Stability of structured and unstructured peptides was evaluated by incubation with 2 mg/mL OPM2 
lysates at 37 °C. Samples were removed from the enzymatic mixture at the indicated time points 
and separated using CE to identify and quantify the area of the peak corresponding to the parent 
peptide. Percent of intact peptide was calculated by dividing the area of the peak corresponding to 
the parent peptide by the total amount of fluorescence. The structured, β-hairpin degron OWRWR 
(black squares, t1/2=626.2 minutes) was substantially more resistant to degradation than its 
unstructured counterpart Scram-OWRWR (blue circles, t1/2=27.9 minutes) as evidenced by having 
a substantially greater amount of intact peptide and significantly higher half-life. An unstructured, 
rapidly degraded peptide (III-67B) was used as a positive control to demonstrate the activity of the 
OPM2 lysates (red triangles, t1/2=3.96 minutes). The 0 minute time point used heat-killed lysates 
and served as the baseline for intact peptide. n=3. 
103 
 
 
Figure 4.7 Selective inhibition of OWRWR ubiquitination in cell lysates. OWRWR peptide 
(10 μM) was incubated in HeLa S100 lysates for 2 hours at 37 °C in the presence of 
commercially-available E1 and E3 enzyme inhibitors.  OWRWR (10 μM) was incubated in 
HeLa S100 cytosolic lysates for 2 hours.  For inhibitor studies, E1 and E3 enzyme inhibitors 
were added 1 hour before the reaction. Each inhibitor was added with the following 
concentrations: nutlin-3 (0.27 μM), serdementan (30 μM), SKPin C1 (150 μM), SMER3 (300 
μM), thalidomide (90 μM), PYR-41 (30 μM), or a DMSO control. 
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Chapter 5: Adapting OWRWR to Analysis by Capillary Electrophoresis 
5.1 Introduction  
Ubiquitination, the conjugation of ubiquitin to proteins by components in the ubiquitin 
proteasome system (UPS), is a versatile post-translational modification (PTM), governing both 
proteasome-mediated degradation as well as key signaling pathways responsible for cell 
homeostasis.1-3  Ubiquitination is principally carried out by E3 ligases, a diverse class of 
enzymes with at least 600 known in humans, organized into several families.4  E3 ligases serve 
two major functions: (1) recognize target proteins for ubiquitination, and (2) facilitate the 
conjugation of ubiquitin to that protein, either directly or by bringing the protein and other 
elements of the UPS into close proximity with each other.5 
Dysregulation of E3 ligases, as well as other UPS components, is suspected to play key roles 
in several human diseases including cancers and neurodegenerative disorders; this has prompted 
intense interest in developing therapeutics targeting E3 ligases as well as other components of 
the UPS.6  The most prominent of these drugs are the blockbuster proteasome inhibitors 
Bortezomib and Carfilzomib; however, a slew of new drugs targeting numerous different 
components of the UPS are currently in clinical trials.7-10  E3 ligases in particular are thought to 
be a fertile ground for such therapeutics, with drugs targeting E3 ligases including HDM2, 
cereblon, p97, and Parkin currently in clinical trials or approved for treatment.7    
Research into E3 ligases is made difficult due to a lack of tools for directly assessing 
enzymatic activity. The self-regulatory nature of the UPS can confound proxy measurements for 
activity such as mRNA analysis, and Western blots, the gold standard, are limited by both their 
sample size requirements and the lack of specific antibodies.1  Techniques such as FRET (Förster 
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resonance energy transfer) sensors, can directly measure E3 ligases activity and have been used 
to efficiently screen large numbers of compounds for E3 ligase inhibition, but these techniques 
require genetic engineering approaches as well as large sample sizes.11  This leaves a gap in 
existing technologies for techniques compatible with small sample sizes, such as primary patient 
samples.  Peptide-based reporters represent a new technique to fill this niche, but have only been 
analyzed using large scale techniques such as SDS-PAGE.12 
This chapter reports on the development of a capillary electrophoresis (CE)-based assay 
using a previously described degradation resistant peptide reporter, OWRWR, that is 
ubiquitinated in cell lysates.  This was done by identifying the electrophoretic separation 
conditions required for sub micro-molar analysis of ubiquitin by CE, and then optimizing the 
separation between ubiquitin and OWRWR.  Following the identification of separation 
conditions, analysis of OWRWR was validated using both a recombinant enzyme ubiquitination 
assay as well as a cell-based ubiquitination assay.  This work lays the foundation for further CE 
analysis optimization towards the analysis of very small numbers of cells. 
5.2 Experimental Design  
5.2.1 CE analysis 
Samples were analyzed using a Beckman Coulter ProteomeLab™ PA800 automated CE 
system (Brea, CA) (CE-LIF, 488 nm) as previously described.13  CE analysis was carried out by 
Gregery Woss, with buffers prepared with the assistance of Joshua Mu.  Prior to CE analysis, 
samples were thawed to room temperature and diluted in separation buffer.  The capillary was 
washed with 1 M NaOH for 5 minutes, dH2O for 5 minutes, and separation buffer for 5 minutes 
by applying 20 psi to the capillary inlet.  Separation was carried out in a fused-silica capillary (30 
μm inner capillary, 360 μm outer capillary, Polymicro Technologies, Pheonix, AZ) with a total 
length of 30 cm and an effective length of 20 cm.  Samples were injected into the capillary by 
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applying 0.5 psi to the capillary inlet for 5 seconds, and separation was initiated by applying a 
negative voltage to the outlet as determined by an Ohm’s plot for each buffer.  Analytes were 
quantified by calculating by the corrected area under the parent peptide peak divided by the total 
corrected peak area (i.e., the area under all peaks of the electropherogram) for each time point. 
The identity of each peak was confirmed using analytes alone or by spiking samples with 
standards. The data was analyzed using commercial software (32 Karat, version 8.0, Beckman 
Coulter). All optimization analyses were performed in triplicate. 
5.2.3 Tissue Culture 
HeLa S100 lysates were generated to provide components of the UPS that could be used 
reproducibly and consistently throughout the development process.  Tissue culture was carried 
out by Gregery Woss.  HeLa S3 cells (ATCC, Manassas, VA) were grown in Dulbecco’s 
modified eagle medium (DMEM) with 10% v/v bovine calf serum (HyClone, GE Healthcare 
Logan, UT) and maintained in a 37 °C, 5% CO2 environment.  Cells were initially grown in T-75 
culture flasks until 70% confluent.  Cells were then rinsed with phosphate-buffered saline (PBS) 
and treated with 2 mL trypsin-EDTA for 5 minutes or until detached, at which point they were 
spun down at 800-1200g for 10 minutes, resuspended in fresh media, and expanded into 
additional flasks.  Once 8 flasks had reached 70% confluence, cells were treated with trypsin-
EDTA as described above and re-suspended in suspension growth media (RPMI 1640 
supplemented with 5% v/v bovine calf serum) to a density of 2 x 105 cells/mL in a 250 mL 
spinner flask.  Cells were allowed to grow with fresh media added to prevent exceeding a cell 
density of 5 x 105 cells/mL.  After 2-3 days of growth, cells were spun down at 800-1200g for 10 
minutes and resuspended in fresh media in a 1 L spinner flask.  This process was repeated until 
the suspension volume reached 1 L, at which point the above process was repeated, and the cells 
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were transferred to a 3 L spinner flask to grow with fresh media added until the suspension 
reached a volume of 3 L and a density of 4-6 x 105 cells/mL, when the cells were harvested.  
Cells were spun out of solution as described above, then washed with ice cold PBS and pelleted 
at 1200g for 10 minutes.  The cell pellet volume was recorded as packed cell volume (PCV). 5X 
PCV hypotonic buffer (10 mM HEPES pH 8.0, 10 mM KCl, 1.5 mM MgCl2, and 1 mM DTT) 
was used to swell the cells over the course of 10 minutes at 4 °C, at which point cells were 
centrifuged at 1800g for 10 minutes.  This pellet was resuspended in 2X PCV in hypotonic 
buffer and lysed with approximately 10 strokes in a Dounce glass homogenizer.  The resulting 
lysed cells were centrifuged for 10 minutes at 1200g. 
Following centrifugation, the resulting supernatant was collected and supplemented with 
0.11X PCV of buffer B (0.3 M HEPES pH 8.0, 1.4 M KCl, and 30 mM MgCl2).  This solution 
was centrifuged at 100,000g for 60 minutes at 4 °C. The supernatant was collected and dialyzed 
twice, first overnight and again for 4 hours, in buffer D (20 mM HEPES pH 8.0, 100 mM KCl, 
0.2 mM EDTA, 0.5 mM PMSF, 1 mM DTT, and 20% v/v glycerol) at 4 °C. The lysate was 
centrifuged one final time at 33,000g for 20 minutes at 4 °C.  The cytosolic lysates were 
quantified using a Nanodrop 2000 (Thermo Scientific), aliquoted, and stored at -80 °C. 
5.2.4 In vitro OWRWR ubiquitination assay using recombinant enzymes 
OWRWR-Ubiquitin analytes were prepared using an in vitro ubiquitination assay using 
recombinant human enzymes.  These reactions were carried out by Gregery Woss.  The reaction 
buffer was composed of 10 mM Tris-HCl (pH 7.6), 5 mM MgCl2, 2 mM DTT, 800 μg/mL 
ubiquitin (Boston Biochem, Cambridge, MA), 1X ATP (Sigma-Aldrich, Saint Louis, MO), 1.5 
μM Ube1 (E1, Boston Biochem, Cambridge, MA), and 15 μM UbcH5b (E2, Boston Biochem, 
Cambridge, MA).  Reactions were carried out at 37 °C for 4 hours, then all reagents other than 
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peptide were replenished.  This replenishment was carried out again at 8 hours, and at 12 hours 
the reaction was halted by heating at 90 °C for 5 minutes. For analysis by gel electrophoresis, 
samples were mixed 2:1 with Tricine Sample Buffer (Bio-Rad, Hercules, CA) and loaded into 
precast 16.5% Mini-PROTEAN Tris Tricine SDS-PAGE gels (Bio-Rad, Hercules, CA). Gels 
were visualized with a Typhoon Imager (GE Healthcare Life Sciences, Pittsburgh, PA). 
Quantification of gels was done using ImageJ software (US National Institute of Health).  
5.2.5 Cell lysate ubiquitination assay/Ubiquitin pulldown assay 
Peptides were evaluated for ubiquitination activity in HeLa S100 or K562 lysates.  These 
reactions were carried out by Gregery Woss.  A reaction buffer was prepared containing 10 mM 
Tris-HCl pH. 7.6, 5 mM MgCl2, 2 mM DTT, 20 μg per mL ubiquitin aldehyde (Boston 
Biochem), 800 μg/mL ubiquitin (Boston Biochem), 1X ATP (Sigma-Aldrich, Saint Louis, MO), 
and HeLa S100 cytosolic lysates or K562 lysates diluted to a set concentration.  For some 
experiments, ubiquitinated reporter was confirmed using a ubiquitin pull-down assay.  Following 
incubation, samples were incubated with Control-Agarose beads (LifeSensors), diluted in TBS-T 
buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, and 0.1% v/v Tween-20), for 60 minutes on a 
tube rotator at 4 °C.  Samples were subsequently centrifuged at 1800g for 5 minutes to pellet and 
remove control beads.  The supernatant was transferred to a solution of Agarose-TUBEs 
(LifeSensors, Malvern, PA), diluted in TBS-T, and incubated overnight on a tube rotator at 4 °C.  
Ubiquitin-bound beads were washed 5X with 1X TBS-T and the samples were eluted off the 
bead by incubating with either 2X tricine sample buffer, or 1X 1 mg/ml ubiquitin and heated for 
5 minutes  at 90 °C followed by centrifugation for 5 minutes at 13000 X g.  
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5.2.6 Data Analysis 
Data was analyzed using commercial software (32 Karat, version 8.0, Beckman Coulter) to 
calculate the following parameters: the width of each peak (𝑊1
2,
𝑂𝑊𝑅𝑊𝑅
,𝑊1
2
𝑂𝑊𝑅𝑊𝑅−𝑈𝑏
), and the 
migration time of each peak (𝑡𝑂𝑊𝑅𝑊𝑅 , 𝑡𝑂𝑊𝑅𝑊𝑅−𝑈𝑏).  Data was analyzed by Gregery Woss.  
These variables were used to calculate resolution (R) and the number of theoretical plates (N) 
using the following equations:  
𝑊1
2,𝐴𝑣𝑔
=
𝑊1
2,𝑂𝑊𝑅𝑊𝑅
+𝑊1
2𝑂𝑊𝑅𝑊𝑅−𝑈𝑏
2
 
𝑅 =
0.589(𝑡𝑂𝑊𝑅𝑊𝑅 − 𝑡𝑂𝑊𝑅𝑊𝑅−𝑈𝑏)
𝑊1
2𝐴𝑣𝑔
 
𝑁 =
5.55𝑡2
𝑊1
2𝐴𝑣𝑔
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5.3 Results and Discussion  
Capillary electrophoresis has been successfully used to separate and quantitate samples with 
ubiquitin moieties in several reports throughout the literature.14, 15  These separations have been 
carried out at relatively high concentrations of ubiquitin (> 1 μM), using either high 
concentrations of salt or detergent, or highly acidic buffers.  However, in order to function as a 
diagnostic tool, the separation of OWRWR and Ub-OWRWR must be demonstrably fast, 
efficient, capable of detecting ubiquitin at nano-molar concentrations, and highly reproducible.  
Preliminary experiments were carried out using ubiquitin conjugated to a single FAM tag (FAM-
Ub), which provided a readily available and inexpensive proxy for OWRWR-ubiquitin.  
Experiments using reported buffer compositions demonstrated a non-linear decrease in signal 
versus the concentration of FAM-Ub at sub-milli-molar concentrations, suggesting that the 
globular ubiquitin was potentially adsorbing to the walls of the capillary.  When an initial buffer 
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screen using common buffers failed to identify conditions that recovered signal at sub-milli-
molar FAM-Ub concentrations, an extensive buffer screen was carried out using combinations of 
buffers in conjunction with a diverse range of additives (Table 5.1).  Interestingly, the addition of 
unlabeled ubiquitin to buffers recovered the FAM-Ub signal down to the micro-molar level, 
providing some evidence that ubiquitin was adhering to the walls of the capillary; however, this 
proved to be an unreliable and expensive additive.  Several high salt buffers were able to produce 
micro-molar levels of sensitivity; however, a single buffer additive, polysorbate 20 (TWEEN 20, 
Sigma-Aldrich, Saint Louis, MO) was capable of recovering FAM-Ub signal into the nano-molar 
range.  This additive was paired with a buffer salt that had previously performed well, sodium 
tetraborate, to produce a starting point for an optimization screen for the separation of OWRWR 
and FAM-Ub.  The concentration of polysorbate 20 (Figure 5.1A), buffer salt concentration 
(Figure 5.1B), and buffer pH (Figure 5.1C), were iterated in order to optimize the resolution and 
theoretical plates for each analyte.  The optimized separation in shown in Figure 5.1D (125 mM 
sodium tetraborate with 3% TWEEN 20 at pH 8.5), with the resolution between analytes being 
14.5 and the theoretical plates being 25,000 and 31,500 for OWRWR and FAM-Ub, respectively. 
Following the identification of separation conditions using OWRWR and FAM-Ub, the next step 
was to validate the separation using OWRWR and ORWRW-Ubiquitin.  While ORWRW-
Ubiquitin is difficult to chemically synthesize, OWRWR is ubiquitinated in cell lysates.  This 
can serve as a source of OWRWR-Ubiquitin; however, the ubiquitination reaction occurs at a 
similar rate to degradation reactions, potentially confounding analysis.    Previous experiments in 
the last chapter demonstrated that OWRWR ubiquitination was diminished when lysates were 
treated with inhibitors of the SCF family of E3 ligases, behavior that had previously been 
observed in a minimal p53 based reporter.16  This suggested that OWRWR could potentially be 
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ubiquitinated by the same recombinant enzymes, Ube1 (an E1 activating enzyme) and UbcH5b 
(and E3 conjugating enzyme).  Control experiments (Figure 5.2A) and pulldown experiments 
(Figure 5.2B) demonstrated the ubiquitination of OWRWR in the presence of these enzymes, 
resulting in a relatively clean OWRWR-Ubiquitin standard.  OWRWR and OWRWR-Ubiquitin 
were cleanly separated using the previously identified CE buffer, as demonstrated in Figure 5.3. 
Following the confirmation that OWRWR and OWRWR-Ubiquitin could be separated by 
CE, further experiments were carried out to demonstrate that OWRWR-Ubiquitin formation 
could be observed in cell lysate experiments by CE.  The results of these experiments show an 
OWRWR-Ubiquitin peak that migrates at the expected time, and can be confirmed by spiking 
experiments (Figures 5.4).  An unidentified peak, mostly likely a degradation fragment of 
OWRWR, migrates very close to the OWRWR-Ubiquitin peak, making precise quantification of 
the peak difficult.  Though not yet complete, this work marks the first time the ubiquitination of 
a peptide reporter has been observed by CE, laying the ground work for future separations 
optimizations. 
5.4 Conclusions 
CE separation conditions were identified for the analysis of the peptide reporter OWRWR.  
Buffer conditions were identified and optimized for the separation of OWRWR and FAM-Ub 
following an extensive buffer screen.  Cell-free recombinant enzyme ubiquitination experiments 
using OWRWR produced OWRWR-Ubiquitin standards, which were used to confirm the 
separation of OWRWR and OWRWR-Ubiquitin.  Finally, the ubiquitination of OWRWR in cell 
lysates was observed by CE, a first for peptide-based E3 ligase reporters.   
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5.5 Figures and Tables   
Figure 5.1 Optimization of OWRWR FAM-Ubiquitin Speraration.  The effect of 
TWEEN 20 (A), sodium tetrabroate (B), and pH (C) on the separation of OWRWR and 
FAM-Ub; 125 mM sodium tetraborate with 3% TWEEN 20 at pH 8.5 was selected to 
maximize the number of theortical plates for each species while retaining a high level of 
resolution.  (D) The separation of OWRWR (1) and FAM-Ub (2) using optimized buffer 
condtions. 
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Figure 5.2 In vitro ubiquitination of OWRWR.  A) OWRWR is ubiquitinated when 
incubated in the presence of Ube1 (E1) and UbcH5b (E2) ATP and ubiquitin.  
Ubiquitination can be seen at ~12 kDa and ~20 kDa.  B) Ubiquitination bands were 
confirmed using a pull down assay. 
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Figure 5.3 CE Analysis of OWRWR Ubiquitination.  Electropherograms showing the 
formation of ubiquitinated products from an in vitro ubiquitination assay.  Peaks (1) and (2) were 
confirmed as parent OWRWR and a peptide impurity, respectively, by standard spiking 
experiments.  Peak (3) corresponds to ubiquitinated product.  Data is zoomed in for clarity, peak 
(1) does not maximize the signal (not shown). 
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Figure 5.4 CE Analysis of OWRWR Ubiquitination in K562 Lysates.  (A) Electropherogram 
showing the formation of ubiquitinated products from a cell lysate ubiquitination assay.  The 
peak indicated by the blue arrow corresponds to ubiquitinated product. Data is zoomed in for 
clarity, peak (1) does not maximize the signal (not shown).  (B) Spiking experiment confirm the 
indicated peak as ubiquitinated OWRWR. 
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Table 5.1 List of Buffer Salts and Additives Screened 
 
  
Buffer Salts  Additives 
Borate  2-propanol 
CAPS 
 3-(N,N-Dimethylpalmitylammonio) 
propanesulfonate17 
Glycine  Sodium dodecyl sulfate (SDS)  
HEPES  Cetrimonium bromide (CTAB) 
MOPS  Cyclodextrin 
Sodium Bicarbonate  Dextrin 
Sodium Citrate  N,N-dimethylacrylamide 
Sodium Phosphate  Polyethylene glycol (PEG) 
Sodium Tetraborate  Polyvinylpyrrolidone 
Tricine  Putrescine 
Tris  Sodium deoxycholate (SDC)  
  Spermine 
  Sulfobutylether-β-cyclodextrin 
  Tween 20 
  Ubiquitin 
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